WO2003040170A9 - Antibodies to cd40 - Google Patents
Antibodies to cd40Info
- Publication number
- WO2003040170A9 WO2003040170A9 PCT/US2002/036107 US0236107W WO03040170A9 WO 2003040170 A9 WO2003040170 A9 WO 2003040170A9 US 0236107 W US0236107 W US 0236107W WO 03040170 A9 WO03040170 A9 WO 03040170A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- antibody
- light chain
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the CD40 antigen is a 50 kDa cell surface glycoprotein which belongs to the Tumor Necrosis Factor Receptor (TNF-R) family.
- TNF-R Tumor Necrosis Factor Receptor
- CD40 is expressed in many normal and tumor cell types, including B lymphocytes, dendritic cells, monocytes, macrophages, thymic epithelium, endothelial cells, fibroblasts, and smooth muscle cells.
- CD40 is expressed in all B-lymphomas and in 70% of all solid tumors.
- CD40 is up-regulated in antigen presenting cells by maturation signals, such as LPS, IL-lj8, -FN- ⁇ and GM-CSF.
- maturation signals such as LPS, IL-lj8, -FN- ⁇ and GM-CSF.
- CD40 activation plays a critical role in regulating humoral and cellular immune responses. Antigen presentation without CD40 activation can lead to tolerance, while CD40 signaling can reverse such tolerance, enhance antigen presentation by all antigen presenting cells (APCs), lead to secretion of helper cytokines and chemokines, increase co-stimulatory molecule expression and signaling, and stimulate cytolytic activity of immune cells.
- APCs antigen presenting cells
- CD40 plays a critical role in B cell proliferation, maturation and class switching.
- CD40 signaling pathway Disruption of the CD40 signaling pathway leads to abnormal serum immunoglobulin isotype distribution, lack of CD4+ T cell priming, and defects in secondary humoral responses.
- the X-linked hyper-IgM syndrome is a disease associated with a mutation in the human CD40L gene, and it is characterized by the inability of affected individuals to produce antibodies other than those of the IgM isotype, indicating that the productive interaction between CD40 and CD40L is required for an effective immune response.
- CD40 engagement by CD40L leads to the association of the CD40 cytoplasmic domain with TRAFs (TNF-R associated factors). (Lee H.H. et al., Proc. N ⁇ tl.
- adhesion molecules e.g., ICAM
- ICAM adhesion molecules
- Lee H.H. et al. Proc. Natl. Acad. Sci. USA. 96:1421-6 (1999); Grousson L et al., Archives of Dermatol. Res. 290:325-30 (1998); Katada Y. et al., Europ. J. of Immunol. 26:192-200 (1996); Mayumi M. et al., J. of Allergy & Clin. Immunol. 96:1136-44 (1995); Flores-Romo L. et al., Immunol.
- ICAM adhesion molecules
- CD40 activation include: cell recruitment and differentiation by chemokines and cytokines; activation of monocytes; increased cytolytic activity of cytolytic T lymphocyte (CTL) and natural killer (NK) cells; induction of apoptosis in CD40 positive tumors; enhancement of immunogenicity of CD40 positive tumors; and tumor-specific antibody production.
- CTL cytolytic T lymphocyte
- NK natural killer
- CD40 activation converts otherwise tolerogenic, antigen bearing B cells into competent APCs.
- CD40 activation induces maturation and differentiation of cord blood progenitors into dendritic cells.
- CD40 activation also induces differentiation of monocytes into functional dendritic cells. (Brossart P. et al., Blood 92:4238-47 (1998).) Further, CD40 activation enhances cytolytic activity of NK cells through APC-CD40 induced cytokines. (Carbone E. et al., J. of Exp. Med. 185:2053-60 (1997); Martin-Fontecha A. et al., J. of Immunol.
- CD40 plays an essential role in the initiation and enhancement of immune responses by inducing maturation of APCs, secretion of helper cytokines, upregulation of costimulatory molecules, and enhancement of effector functions.
- the critical role of CD40 signaling in the initiation and maturation of humoral and cytotoxic immune responses makes this system an ideal target for immune enhancement.
- Such enhancement can be particularly important for mounting effective immune responses to tumor antigens, which are generally presented to the immune system through cross-priming of activated APCs.
- CD40 is expressed in lymphomas, leukemias, multiple myeloma, a majority of carcinomas of nasopharynx, bladder, ovary, and liver, and some breast and colorectal cancers, activation of CD40 can have a broad range of clinical applications.
- Anti-CD40 activating monoclonal antibodies can contribute to tumor eradication via several important mechanisms. Foremost among these is activation of host dendritic cells for enhanced tumor antigen processing and presentation, as well as enhanced antigen presentation or immunogenicity of CD40 positive tumor cells themselves, leading to activation of tumor specific CD4 + and CD8 + lymphocytes. Additional antitumor activity can be mediated by other immune- enhancing effects of CD40 signaling (production of chemokines and cytokines, recruitment and activation monocytes, and enhanced CTL and NK cytolytic activity), as well as direct killing of CD40 + tumors by induction of apoptosis or by stimulating a humoral response leading to ADCC. Apoptotic and dying tumor cells can also become an important source of tumor-specific antigens that are processed and presented by CD40 activated APCs.
- Figures 1A-1H are sequence alignments of predicted amino acid sequences of isolated anti-CD40 monoclonal antibody light and heavy chain variable domains with the germline amino acid sequences of the corresponding light and heavy chain genes.). Differences between the clones and the germline sequence are indicated by shading. The germline CDR1, CDR2, and CDR3 sequences are underlined. In alignments of heavy chain sequences, apparent insertions to the CDR3 region are indicated by a dash (-) in the germline sequence and apparent deletions in the CDR3 region are indicated by a dash (-) in the clone sequence.
- Figure IC the predicted kappa light chain variable region amino acid sequences from mAbs 10.8.3 and 21.4.1 and the germline amino acid sequence
- Figure 2A-2H are sequence alignments of predicted amino acid sequences of isolated anti-CD40 monoclonal antibody light and heavy chain variable domains with the germline amino acid sequences of the corresponding light and heavy chain genes.). Differences between the clones and the germline sequence are indicated in bold. The germline CDR1, CDR2, and CDR3 sequences are underlined.
- Figure 2B the predicted kappa light chain amino acid sequence from mAb 21.2.1 and the germline amino acid sequence
- Figure 2D the predicted heavy chain amino acid sequence from mAb
- Figure 3 is a dose-response curve that illustrates the ability of an anti- CD40 antibody of the invention (21.4.1) to enhance IL-12p40 production by human dendritic cells.
- Figure 4 is a dose-response curve that illustrates the ability of an anti- CD40 antibody of the invention (21.4.1) to enhance IL-12p70 production by human dendritic cells.
- Figure 5 is a graph that illustrates the ability of an anti-CD40 antibody of the invention (21.4.1) to increase immunogenicity of Jy stimulator cells and enhance CTL activity against Jy target cells.
- Figure 6 is a tumor growth inhibition curve that illustrates the reduced growth of CD40 positive Daudi tumors in SCID-beige mice treated with an anti- CD40 antibody of the invention (21.4.1).
- Figure 7 is a tumor growth inhibition curve that illustrates the reduced growth of CD40 negative K562 tumors in SCID-beige mice treated with an anti- CD40 antibody of the invention (21.4.1) and human dendritic cells and T cells.
- Figure 8 shows inhibition in the growth of CD40 negative K562 tumors in SCID mice by different concentrations of anti-CD40 agonist mAb 23.29.1.
- Figure 9 shows inhibition in the growth of CD40 negative K562 tumors in SCID mice by different concentrations of anti-CD40 agonist mAb 3.1.1.
- Figure 10 shows inhibition in the growth of CD40 positive Raji tumors in the presence and absence of T cells and dendritic cells in SCID mice by an anti- CD40 agonist mAb.
- Figure 11 shows inhibition in the growth of CD40 positive Raji tumors in SCID mice by anti-CD40 agonist antibodies.
- Figure 12 shows inhibition in the growth of BT 474 breast cancer cells in SCID-beige mice by anti-CD40 agonist antibodies.
- Figure 13 shows inhibition in the growth of PC-3 prostate tumors in SCID-beige mice by anti-CD40 agonist antibodies.
- Figure 14 is a survival curve for SCID-beige mice injected (iv) with Daudi tumor cells and treated with anti-CD40 agonist antibodies.
- Figure 15 is a Western blot analysis of anti-CD40 agonist antibodies to reduced (R) and non-reduced (NR) human CD40.
- Figure 16 is an alignment of the D1-D4 domains of mouse and human CD40.
- Figure 17 is an alignment of the mouse and human CD40 amino acid sequences showing the location of the fusion sites of the chimeras.
- Figure 18 is a group of schematic diagrams of the chimeric CD40 constructs.
- the present invention provides an isolated antibody or antigen-binding portion thereof that binds CD40 and acts as a CD40 agonist.
- the invention provides a composition comprising the anti-CD40 antibody, or antigen binding portion thereof, and a pharmaceutically acceptable carrier.
- the composition may further comprise another component, such as an anti-tumor agent or an imaging agent. Diagnostic and therapeutic methods are also provided by the invention.
- the invention provides an isolated cell line, such as a hybridoma, that produces an anti-CD40 antibody or antigen binding portion thereof. [0049]
- the invention also provides nucleic acid molecules encoding the heavy and/or light chain, or antigen-binding portions thereof, of an anti-CD40 antibody.
- the invention provides vectors and host cells comprising the nucleic acid molecules, as well as methods of recombinantly producing the polypeptides encoded by nucleic acid molecules.
- Non-human transgenic animals that express the heavy and/or light chain, or antigen-binding portions thereof, of an anti-CD40 antibody are also provided.
- the invention also provides a method for treating a subject in need thereof with an effective amount of a nucleic acid molecule encoding the heavy and/or light chain, or antigen-binding portions thereof, of an anti-CD40 antibody.
- polypeptide encompasses native or artificial proteins, protein fragments and polypeptide analogs of a protein sequence.
- a polypeptide may be monomeric or polymeric.
- isolated protein is a protein, polypeptide or antibody that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature.
- a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be “isolated” from its naturally associated components.
- a protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.
- Examples of isolated antibodies include an anti-CD40 antibody that has been affinity purified using CD40, an anti-CD40 antibody that has been synthesized by a hybridoma or other cell line in vitro, and a human anti-CD40 antibody derived from a transgenic mouse.
- a protein or polypeptide is "substantially pure,” “substantially homogeneous,” or “substantially purified” when at least about 60 to 75% of a sample exhibits a single species of polypeptide.
- the polypeptide or protein may be monomeric or multimeric.
- a substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure.
- Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.
- polypeptide fragment refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence.
- fragments are at least 5, 6, 8 or 10 amino acids long.
- the fragments are at least 14 , at least 20, at least 50, or at least 70, 80, 90, 100, 150 or 200 amino acids long.
- polypeptide analog refers to a polypeptide that comprises a segment that has substantial identity to a portion of an amino acid sequence and that has at least one of the following properties: (1) specific binding to CD40 under suitable binding conditions, (2) ability to activate CD40, (3) the ability to upregulate the expression of cell surface molecules such as ICAM, MHC- ⁇ , B7-1, B7-2, CD71, CD23 and CD83, or (4) the ability to enhance the secretion of cytokines such as IFN-/31, IL-2, IL-8, IL-12, IL-15, IL-18 and IL-23.
- polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence.
- Analogs typically are at least 20 or 25 amino acids long, preferably at least 50, 60, 70, 80, 90, 100, 150 or 200 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.
- Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, and (4) confer or modify other physicochemical or functional properties of such analogs.
- Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts).
- a conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary stracture that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles
- ⁇ on-peptide analogs are commonly used in the pharmaceutical industry as drags with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics” or “peptidomimetics.” Fauchere, J. Adv. Drug Res. 15:29 (1986); Neber and Freidinger, TINSp.392 (1985); and Evans et al, J. Med. Chem. 30:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect.
- a paradigm polypeptide i.e., a polypeptide that has a desired biochemical property or pharmacological activity
- Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type may also be used to generate more stable peptides.
- constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch, Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.
- an "antibody” refers to a complete antibody or to an antigen-binding portion thereof, that competes with the intact antibody for specific binding. See generally, Fundamental Immunology. Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). Antigen- binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies.
- Antigen-binding portions include, z.zter alia, Fab, Fab', F(ab') 2 , Fd, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an antibody that is sufficient to confer specific antigen binding to the polypeptide.
- CDR complementarity determining region
- an antibody that is referred to by number is a monoclonal antibody that is obtained from the hybridoma of the same number.
- monoclonal antibody 3.1.1 is obtained from hybridoma 3.1.1.
- a Fd fragment means an antibody fragment that consists of the V H and C H 1 domains; an Fv fragment consists of the N and V H domains of a single arm of an antibody; and a dAb fragment (Ward et al., Nature 341:544-546 (1989)) consists of a V H domain.
- the antibody is a single-chain antibody (scFv) in which a V L and V H domains are paired to form a monovalent molecules via a synthetic linker that enables them to be made as a single protein chain.
- scFv single-chain antibody
- the antibodies are diabodies, i.e., are bivalent antibodies in which V H and V L domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites.
- diabodies i.e., are bivalent antibodies in which V H and V L domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites.
- one or more CDRs from an antibody of the invention may be incorporated into a molecule either covalently or noncovalently to make it an immunoadhesin that specifically binds to CD40.
- the CDR(s) may be incorporated as part of a larger polypeptide chain, may be covalently linked to another polypeptide chain, or may be incorporated noncovalently.
- the binding sites may be identical to one another or may be different.
- human antibody means any antibody in which all of the variable and constant domain sequences are human sequences. These antibodies may be prepared in a variety of ways, as described below.
- chimeric antibody as used herein means an antibody that comprises regions from two or more different antibodies.
- one or more of the CDRs are derived from a human anti-CD40 antibody.
- all of the CDRs are derived from a human anti-CD40 antibody.
- the CDRs from more than one human anti-CD40 antibodies are combined in a chimeric antibody.
- a chimeric antibody may comprise a CDR1 from the light chain of a first human anti-CD40 antibody, a CDR2 from the light chain of a second human anti-CD40 antibody and a CDR3 and CDR3 from the light chain of a third human anti-CD40 antibody, and the CDRs from the heavy chain may be derived from one or more other anti-CD40 antibodies.
- the framework regions may be derived from one of the same anti-CD40 antibodies or from one or more different human.
- An "activating antibody” also referred to herein as an "agonist antibody” as used herein means an antibody that increases one or more CD40 activities by at least about 20% when added to a cell, tissue or organism expressing CD40.
- the antibody activates CD40 activity by at least 40%, 50%, 60%, 70%), 80%), 85%.
- the activating antibody is added in the presence of CD40L.
- the activity of the activating antibody is measured using a whole blood surface molecule upregulation assay. See Example VII.
- the activity of the activating antibody is measured using a dendritic cell assay to measure IL-12 release. See Example VIII.
- the activity of the activating antibody is measured using an in vivo tumor model. See Example X. *
- fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art following the teachings of this specification.
- Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains.
- Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases.
- computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known stracture and/or function. Methods to identify protein sequences that fold into a known three-dimensional stracture are known. See Bowie et al., Science 253:164 (1991).
- the term "surface plasmon resonance”, as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.).
- BIAcore Phharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.
- K D refers to the equilibrium dissociation constant of a particular antibody-antigen interaction.
- epitopic determinants includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor.
- Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
- An antibody is said to specifically bind an antigen when the equilibrium dissociation constant is -.1 ⁇ M, preferably --100 nM and most preferably --10 nM.
- the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology - A Synthesis (2 nd
- polynucleotide as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide.
- the term includes single and double stranded forms.
- isolated polynucleotide as used herein means a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide” (1) is not associated with all or a portion of a polynucleotides with which the "isolated polynucleotide” is found in nature, (2) is operably linked to a polynucleotide to which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.
- oligonucleotide includes naturally occurring, and modified nucleotides linked together by naturally occurring and non-naturally occurring oligonucleotide linkages.
- Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer.
- Preferably oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length.
- Oligonucleotides are usually single stranded, e.g. for primers and probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant.
- Oligonucleotides of the invention can be either sense or antisense oligonucleotides.
- nucleotides as used herein includes deoxyribonucleotides and ribonucleotides.
- modified nucleotides as used herein includes nucleotides with modified or substituted sugar groups and the like.
- oligonucleotide linkages referred to herein includes oligonucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche et al., Nucl. Acids Res.
- oligonucleotide can include a label for detection, if desired.
- operably linked sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
- expression control sequence means polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated.
- Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion.
- control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence.
- control sequences is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
- the term "vector”, as used herein, means a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- the vector is a plasmid, i.e., a circular double stranded DNA loop into which additional DNA segments may be ligated.
- the vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.
- the vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
- the vectors e.g., non-episomal mammalian vectors
- the vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
- certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, “expression vectors").
- recombinant host cell means a cell into which a recombinant expression vector has been introduced. It should be understood that "recombinant host cell” and “host cell” mean not only the particular subject cell but also the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein. [0085] The term “selectively hybridize” referred to herein means to detectably and specifically bind.
- Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids.
- “High stringency” or “highly stringent” conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein.
- high stringency or “highly stringent” conditions is the incubation of a polynucleotide with another polynucleotide, wherein one polynucleotide may be affixed to a solid surface such as a membrane, in a hybridization buffer of 6X SSPE or SSC, 50% formamide, 5X Denhardt's reagent, 0.5% SDS, 100 j-ig/ml denatured, fragmented salmon sperm DNA at a hybridization temperature of 42°C for 12-16 hours, followed by twice washing at 55°C using a wash buffer of IX SSC, 0.5% SDS. See also Sambrook et al., supra, pp. 9.50-9.55.
- sequence identity in the context of nucleic acid sequences means the residues in two sequences that are the same when aligned for maximum correspondence.
- the length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 18 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36, 48 or more nucleotides.
- polynucleotide sequences can be compared using FASTA, ' Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin.
- FASTA which includes, e.g., the programs
- FASTA2 and FASTA3 provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, Methods Enzymol. 183:63-98 (1990); Pearson, Methods Mol. Biol. 132:185-219 (2000); Pearson, Methods Enzymol. 266:227-258 (1996); Pearson, J. Mol. Biol. 276:71-84 (1998); herein incorporated by reference). Unless otherwise specified, default parameters for a particular program or algorithm are used.
- percent sequence identity between nucleic acid sequences can be deteraiined using FASTA with its default parameters (a word size of 6 and the NOP AM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.
- FASTA FASTA with its default parameters
- Gap Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.
- a reference to a nucleotide sequence encompasses its complement unless otherwise specified.
- a reference to a nucleic acid having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence.
- nucleic acid or fragment thereof when referring to a nucleic acid or fragment thereof, means that when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 85%, preferably at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.
- the term "substantial identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 70, 75 or 80 percent sequence identity, preferably at least 90 or 95 percent sequence identity, and more preferably at least 97, 98 or 99 percent sequence identity.
- residue positions that are not identical differ by conservative amino acid substitutions.
- a “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein.
- the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson, Methods Mol. Biol. 243:307-31 (1994).
- Examples of groups of amino acids that have side chains with similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid; and 7) sulfur-containing side chains: cysteine and methionine.
- Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.
- a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al., Science 256:1443-45 (1992), herein incorporated by reference.
- a “moderately conservative" replacement is any change having a nonnegative value in the
- Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions.
- GCG contains programs such as "Gap” and "Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g., GCG Version 6.1. Polypeptide sequences also can be compared using FASTA using default or recommended parameters, a program in GCG Version 6.1.
- FASTA e.g., FASTA2 and FASTA3
- FASTA2 and FASTA3 provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, Methods Enzymol. 183:63-98 (1990); Pearson, Methods Mol. Biol. 132:185-219 (2000)).
- Another preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially blastp or tblastn, using default parameters. See, e.g., Altschul et al., J. Mol. Biol. 215:403-410 (1990); Altschul et al., Nucleic Acids Res. 25:3389-402 (1997); herein incorporated by reference.
- the length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number of different organisms, it is preferable to compare amino acid sequences.
- label or “labeled” refers to incorporation of another molecule in the antibody.
- the label is a detectable marker, e.g., incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods).
- the label or marker can be therapeutic, e.g., a drag conjugate or toxin.
- Various methods of labeling polypeptides and glycoproteins are known in the art and may be used.
- labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, n l In, 125 I, I31 I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels
- chemiluminescent markers e.g., horseradish peroxidase, /5-galactosidase, luciferase, alkaline phosphatase
- chemiluminescent markers biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), magnetic agents, such as gadolinium chelates, toxins such as pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorabicin, daunorabicin, dihydroxy anthracin dione, mitoxantrone, mithrarnycin, actinomycin D, 1-dehydrotestosterone, glucocortic
- Human antibodies avoid certain of the problems associated with antibodies that possess non-human (e.g., rodent) variable and/or constant regions. Such problems include the rapid clearance of the antibodies or immune response against the antibody. Therefore, in one embodiment, the invention provides humanized anti-CD40 antibodies. In another embodiment, the invention provides human anti-CD40 antibodies. In some embodiments, human anti-CD40 antibodies are produced by immunizing a rodent whose genome comprises human immunoglobulin genes so that the rodent produces human antibodies. Human anti- CD40 antibodies are expected to minimize the immunogenic and allergic responses intrinsic to non-human or non-human-derivatized monoclonal antibodies (Mabs) and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation and cancer, which may require repeated antibody administrations.
- Mabs monoclonal antibodies
- the invention provides eleven activating human anti-CD40 monoclonal antibodies (mAbs) and the hybridoma cell lines that produce them.
- mAbs human anti-CD40 monoclonal antibodies
- able A lists the sequence identifiers (SEQ ID NOS:) of the nucleic acids encoding the full- length heavy and light chains (including leader sequence), the corresponding full- length deduced amino acid sequences, and the nucleotide and deduced amino acid sequence of the heavy and light chain variable regions. Table A
- the invention further provides human anti-CD40 mAb 23.25.1 and the hybridoma cell line that produces it.
- the invention further provides heavy and/or light chain variants of certain of the above-listed human anti-CD40 mAbs, comprising one or more amino acid substitutions.
- the invention provides two variant heavy chains of mAb 3.1.1. In one, the alanine at residue 78 is changed to threonine. In the second, the alanine at residue 78 is changed to threonine, and the valines at residues 88 and 97 are changed to alanines.
- the invention also provides a variant light chain of mAb
- the leucine at residue 4 and the leucine at residue 83 are changed to methionine and valine, respectively.
- Combination with a variant heavy or light chain with a wild type light or heavy chain, respectively is designated by the mutant chain.
- an antibody containing a wild type light chain and a heavy chain comprising the alanine to threonine mutation at residue 78 is designated as 3.1.1H-A78T.
- antibodies containing any combination of a variant heavy chain and the variant light chain of 3.1.1 are included.
- the invention provides a variant of the heavy chain of mAb 22.1.1 in which the cysteine at residue 109 is changed to an alanine.
- a monoclonal antibody comprising the variant heavy chain and the 22.1.1 light chain chain is designated mAb 22.1.1 H-C 109 A.
- the invention further provides two variant heavy chains and a variant light chain of mAb 23.28.1.
- one heavy chain variant the aspartic acid at residue 16 is changed to glutamic acid.
- a mAb comprising the variant heavy chain variant and the 23.28.1 light chain is designated 23.28.1 H- D16E.
- the invention also includes a 23.28.1 light chain variant in which the cysteine at residue 92 is changed to an alanine.
- a mAb comprising the 23.28.1 heavy chain and the variant light chain is designated 23.28.1 L C92A.
- the invention also provides mAbs comprising either of the 23.28.1 heavy chain variants with the 23.28.1 light chain variant.
- the light chain produced by hybridoma 23.29.1 contains a mutation in the constant region at residue 174.
- the light chain produced by the hybridoma has arginine at this position instead of the canonical lysine.
- the invention also provides a 23.29.1 light chain with the canonical lysine at residue 174 and a mAb, designated 23.29.1L-R174K, comprising the 23.29.1 heavy chain and the variant light chain.
- the anti-CD40 antibody is 3.1.1, 3.1.1H- A78T, 3.1.1H-A78T-V88A-V97A, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1,
- the anti-CD40 antibody comprises a light chain comprising an amino acid sequence selected from SEQ ID NO: 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 94, 100 or 102 or the variable region therefrom, or encoded by a nucleic acid sequence selected from SEQ ID NO: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79, 87, 93, 99 or 101.
- the anti-CD40 antibody comprises a light chain comprising at least the CDR2 from one of listed antibodies, one of the above-identified amino acid sequences (as shown in Figs. 1A-1C and 2A-2C) or encoded by one of the above- identified nucleic acid sequences.
- the light chain further comprises a CDR1 and CDR3 independently selected from a light chain variable region that comprises no more than ten amino acids from the amino acid sequence encoded by a germline VK A3/A19, L5 or A27 gene, or comprises a CDRl and CDR3 independently selected from one of a CDRl and CDR3 of (1) an antibody selected from 3.1.1, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K or 24.2.1 ; (2) the amino acid sequence of SEQ ED NO: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94, 100 or 102 or (3) encoded by the nucleic acid sequence of SEQ ID NO: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, 93, 99 or
- the anti-CD40 antibody comprises a heavy chain comprising an amino acid sequence selected from SEQ ID NOS: 6, 14, 22, 30, 38, 46, 54, 62, 70, 78 or 86 or the variable region therefrom or encoded by a nucleic acid sequence selected from SEQ ID NOS: 5, 13, 21, 29, 37, 45, 53, 61, 69, 77 or 85.
- the anti-CD40 antibody comprises a heavy chain comprising at least the CDR3 from one of listed antibodies, one of the above-identified amino acid sequences (as shown in Figs. 1A-1C and 2A-2C) or encoded by one of the above-identified nucleic acid sequences.
- the heavy chain further comprises a CDRl and CDR2 independently selected from a heavy chain variable region that comprises no more than eighteen amino acids from the amino acid sequence encoded by a germline V H 3-30+, 4-59, 1-02, 4.35 or 3-30.3 gene, or comprises a CDRl and CDR2 independently selected from one of a CDRl and CDR2 of ( 1 ) an antibody selected from 3.1.1, 3.1.1 H-
- the anti-CD40 antibody comprises a heavy chain and a light chain as defined above.
- antibody 3.1.1H-A78T is identical to that of 3.1.1 except that residue 78 of the heavy chain is threonine instead of alanine.
- residue 78 of the heavy chain is threonine instead of alanine.
- residue 78 is changed to A, and residues 88 and 97 are changed from valine to alanine in the heavy chain.
- L4M-L83V is identical to that of 3.1.1 except that residue 4 is methionine instead of leucine and residue 83 is valine instead of leucine in the light chain.
- Antibody 22.1.1H-C109A is identical to that of 22.1.1 except that residue 109 of the heavy chain is changed from a cysteine to an alanine.
- Antibodies 23.28.1H-D16E and 23.28.1L-C92A are identical to that of 23.28.1 except that residue 16 of the heavy chain is changed from aspartate to glutamate, and residue 92 of the light chain is changed from cysteine to alanine, respectively.
- Antibody 23.29.1L-R174K is identical to that of 23.29.1 except that residue 174 of the light chain is changed from arginine to lysine.
- the class and subclass of anti-CD40 antibodies may be determined by any method known in the art.
- the class and subclass of an antibody may be determined using antibodies that are specific for a particular class and subclass of antibody. Such antibodies are available commercially.
- the class and subclass can be determined by ELISA, or Western Blot as well as other techniques.
- the class and subclass may be determined by sequencing all or a portion of the constant domains of the heavy and/or light chains of the antibodies, comparing their amino acid sequences to the known amino acid sequences of various class and subclasses of immunoglobulins, and determining the class and subclass of the antibodies.
- the anti-CD40 antibody is a monoclonal antibody.
- the anti-CD40 antibody can be an IgG, an IgM, an IgE, an IgA or an IgD molecule.
- the anti-CD40 antibody is an IgG and is an IgGl, IgG2, IgG3 or IgG4 subclass.
- the anti- CD40 antibodies are subclass IgG2.
- the anti-CD40 antibodies demonstrate both species and molecule selectivity.
- the anti-CD40 antibody binds to primate and human CD40.
- the anti-CD40 antibody binds to human, cynomolgus or rhesus CD40.
- the anti-CD40 antibody does not bind to mouse, rat, dog or rabbit CD40.
- the species selectivity for the anti-CD40 antibody using methods well known in the art. For instance, one can determine species selectivity using Western blot, FACS, ELISA or RIA. (See, e.g., Example IV.)
- the anti-CD40 antibody has a selectivity for CD40 that is more than 100 times greater than its selectivity for RANK (receptor activator of nuclear factor-kappa B), 4- IBB (CD 137), TNFR- 1 (Tumor Necrosis Factor Receptor- 1) and TNFR-2 (Tumor Necrosis Factor Receptor-2).
- the anti-CD40 antibody does not exhibit any appreciable specific binding to any other protein other than CD40.
- the invention provides a human anti-CD40 monoclonal antibody that binds CD40 and cross-competes with and/or binds the same epitope and or binds to CD40 with the same K D as a human anti-CD40 antibody selected from an antibody 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-V88A-V97A, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K or 24.2.1; or a human anti-CD40 antibody that comprises a heavy chain variable region having an amino acid sequence of SEQ ID NO: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98 or a human anti-CD40 antibody selected
- test antibody if the test antibody is not able to bind to the CD40 at the same time, then the test antibody binds to the same epitope, an overlapping epitope, or an epitope that is in close proximity to the epitope bound by the human anti-CD40 antibody.
- This experiment can be performed using ELISA, RIA, FACS or surface plasmon resonance. (See, e.g., Example NI.) In a prefened embodiment, the experiment is performed using surface plasmon resonance. In a more preferred embodiment, BIAcore is used.
- the anti-CD40 antibody binds to CD40 with high affinity. In some embodiments, the anti-CD40 antibody binds to CD40 with a K D of 2 x 10 " M or less. In another preferred embodiments, the antibody binds to CD40 with a K D of 2 x 10 "9 , 2 x 10 "10 , 4.0 x 10 "11 M or less. In an even more prefened embodiment, the antibody binds to CD40 with a K D of 2.5 x 10 "12 M or less.
- the antibody binds to CD40 with substantially the same KD as an antibody selected from 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-N88A-N97A, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1 , 23.29.1L-R174K or 24.2.1.
- the antibody binds to CD40 with substantially the same KD as an antibody that comprises a CDR2 of a light chain, and/or a CDR3 of a heavy chain from an antibody selected from 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-N88A-N97A, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, . 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1, 23.29.1L- Rl 74K and 24.2.1.
- the antibody binds to CD40 with substantially the same KD as an antibody that comprises a heavy chain variable region having an amino acid sequence of SEQ ID NO: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98 or that comprises a light chain having an amino acid sequence of SEQ ID NO: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94, 100 or 102.
- the antibody binds to CD40 with substantially the same K D as an antibody that comprises a CDR2 of " a light chain variable region having an amino acid sequence of SEQ ID NO: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94, 100 or 102 or a CDR3 of a heavy chain variable region having an amino acid sequence of SEQ ID NO: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98.
- the anti-CD40 antibody has a low dissociation rate.
- the anti-CD40 antibody has an K off of 2.0 x 10 "4 or lower.
- the K off is 2.0 x 10 "7 or lower. In some embodiments, the K off is substantially the same as an antibody described herein, including an antibody selected from 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-N88A- N97A, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H- C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K and 24.2.1.
- the antibody binds to CD40 with substantially the same K off as an antibody that comprises a CDR3 of a heavy chain or a CDR2 of a light chain from an antibody selected from 3.1.1, 3.1.1H- A78T, 3.1.1H-A78T-N88A-N97A, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K and 24.2.1.
- the antibody binds to CD40 with substantially the same K off as an antibody that comprises a heavy chain variable region having an amino acid sequence of SEQ ID NO: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98 or that comprises a light chain variable region having an amino acid sequence of SEQ ID NO: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94, 100 or 102.
- the antibody binds to CD40 with substantially the same K off as an antibody that comprises a CDR2 of a light chain variable region having an amino acid sequence of SEQ ID NO: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94, 100 or 102 or a CDR3 of a heavy chain variable region having an amino acid sequence of SEQ ID NO: 6, 14, 22, 30, 38, 46, 54, 62, 70, 78, 86, 90, 92, 96 or 98.
- the binding affinity and dissociation rate of an anti-CD40 antibody to CD40 can be determined by any method known in the art.
- the binding affinity can be measured by competitive ELIS As, RIAs or surface plasmon resonance, such as BIAcore.
- the dissociation rate also can be measured by surface plasmon resonance.
- the binding affinity and dissociation rate is measured by surface plasmon resonance. More preferably, the binding affinity and dissociation rate are measured using a BIAcoreTM. See, e.g., Example XIV. Light and Heavy Chain Gene Usage
- An anti-CD40 antibody of the invention can comprise a human kappa or a human lambda light chain or an amino acid sequence derived therefrom.
- the light chain variable domain (VL) is encoded in part by a human A3/A19 (DPK- 15), L5 (DP5), or A27 (DPK-22) V/c gene.
- the N L of the anti-CD40 antibody contains one or more amino acid substitutions relative to the germline amino acid sequence. In some embodiments, the N L of the anti-CD40 antibody comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions relative to the germline amino acid sequence. In some embodiments, one or more of those substitutions from germline is in the CDR regions of the light chain.
- the amino acid substitutions relative to germline are at one or more of the same positions as the substitutions relative to germline in any one or more of the N L of antibodies 3.1.1, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K and 24.2.1.
- the N L of the anti-CD40 antibody may contain one or more amino acid substitutions compared to germline found in antibody 21.4.1, and other amino acid substitutions compared to germline found in antibody 10.8.3 which utilizes the same N gene as antibody 21.4.1.
- the amino acid changes are at one or more . of the same positions but involve a different mutation than in the reference antibody.
- amino acid changes relative to germline occur at one or more of the same positions as in any of the N L of antibodies 3.1.1, 3.1.1 L- L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K and 24.2.1, but the changes may represent conservative amino acid substitutions at such position(s) relative to the amino acid in the reference antibody. For example, if a particular position in one of these antibodies is changed relative to germline and is glutamate, one may conservatively substitute aspartate at that position. Similarly, if an amino acid substitution compared to germline is serine, one may conservatively substitute threonine for serine at that position. Conservative amino acid substitutions are discussed supra.
- the light chain of the human anti-CD40 antibody comprises the amino acid sequence that is the same as the amino acid sequence of the V L of antibody 3.1.1 (SEQ. LD NO: 4), 3.1.1L-L4M-L83V (SEQ ID NO: 94), 7.1.2 (SEQ. ID NO: 12), 10.8.3 (SEQ. ID NO: 20), 15.1.1 (SEQ. ID NO: 28), 21.4.1(SEQ. ID NO:), 21.2.1 (SEQ. ID NO: 36), 21.4.1 (SEQ ID NO: 44), 22.1.1 (SEQ. ID NO: 52), 23.5.1 (SEQ. ID NO: 60), 23.28.1 (SEQ. ID NO: 68), 23.28.1L-C92A (SEQ.
- the light chain of the anti-CD40 antibody comprises at least the light chain CDR2, and may also comprise the CDRl and CDR3 regions of a germline sequence, as described herein.
- the light chain may comprise a CDRl and CDR2 of an antibody independently selected from 3.1.1, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1, 23.28.1L-C92A, 23.29.1 and 24.2.1, or CDR regions each having less than 8, less than 6, less than 4 or less than 3 conservative amino acid substitutions and/or a total of three or fewer non- conservative amino acid substitutions.
- the light chain of the anti-CD40 antibody comprises at least the light chain CDR2, and may also comprise the CDRl and CDR3 regions, each of which are independently selected from the CDRl and CDR3 regions of an antibody having a light chain variable region comprising the amino acid sequence selected from SEQ ID NOS: 4, 12, 20,
- variable region of the heavy chain amino acid sequence is encoded in part by a human V H 3-30+, V H 4-59, V H 1-02, V H 4.35 or V H 3-30.3 gene.
- the V H of the anti-CD40 antibody contains one or more amino acid substitutions, deletions or insertions (additions) relative to the germline amino acid sequence.
- variable domain of the heavy chain comprises 1, 2, 3, 4, 5, 6, 1, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 mutations from the germline amino acid sequence.
- the mutation(s) are non-conservative substitutions compared to the germline amino acid sequence.
- the mutations are in the CDR regions of the heavy chain.
- the amino acid changes are made at one or more of the same positions as the mutations from germline in any one or more of the V H of antibodies 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-V88A-V97A, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.29.1 and 24.2.1.
- the amino acid changes are at one or more of the same positions but involve a different mutation than in the reference antibody.
- the heavy chain comprises an amino acid sequence of the variable domain (V H ) of antibody 3.1.1 (SEQ JD NO: 2), 3.1.1H-A78T (SEQ ID NO: 90), 3.1.1H-A78T-V88A-V97A (SEQ ID NO: 92), 7.1.2 (SEQ ID NO: 10), 10.8.3 (SEQ ID NO: 18), 15.1.1 (SEQ ID NO: 26), 21.2.1 (SEQ ID NO: 34), 21.4.1 (SEQ ID NO: 42), 22.1.1 (SEQ ID NO: 50), 22.1.1H-C109A (SEQ ID NO: 96), 23.5.1 (SEQ ID NO: 58), 23.28.1 (SEQ ID NO: 66), 23.28.1H-D16E (SEQ ID NO: 98), 23.29.1 (SEQ ID NO: 74) and 24.2.1 (SEQ ID NO: 82), or said amino acid sequence having up to 1, 2, 3, 4, 6, 8 or 10 conservative amino acid substitutions and/or a total
- the heavy chain comprises the heavy chain CDRl, CDR2 and CDR3 regions of antibody 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-N88A- N97A, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.29.1 and 24.2.1 (as shown in Figs. lD-lH or 2D-2H), or said CDR regions each having less than 8, less than 6, less than 4, or less than 3 conservative amino acid substitutions and/or a total of three or fewer non-conservative amino acid substitutions.
- the heavy chain comprises a CDR3, and may also comprise the CDRl and CDR2 regions of a germline sequence, as described above, or may comprise a CDRl and CDR2 of an antibody, each of which are independently selected from an antibody comprising a heavy chain of an antibody selected from 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-N88A-N97A, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H- D16E, 23.29.1 and 24.2.1.
- the heavy chain comprises a CDR3, and may also comprise the CDRl and CDR2 regions, each of which are
- J5 independently selected from a CDRl and CDR2 region of a heavy chain variable region comprising an amino acid sequence selected from SEQ ID ⁇ OS: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98 (as shown in Figs. 1D-1H or Figs. 2D-2H)or encoded by a nucleic acid sequence selected from SEQ ID ⁇ OS: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89, 91, 95 or 97.
- the 0 antibody comprises a heavy chain as disclosed above and a light chain as disclosed above.
- One type of amino acid substitution that may be made is to change one or more cysteines in the antibody, which may be chemically reactive, to another residue, such as, without limitation, alanine or serine.
- the 5 cysteine substitution is made in a framework region of a variable domain or in the constant domain of an antibody.
- the cysteine is in a non- canonical region of the antibody.
- Another type of amino acid substitution that may be made is to change any potential proteolytic sites in the antibody, particularly those that are in a framework region of a variable domain, in the constant domain 0 of an antibody, or in a non-canonical region of the antibody Substitution of cysteine residues and removal of proteolytic sites may decrease the risk of any heterogeneity in the antibody product and thus increase its homogeneity.
- Another type of amino acid substitution is to eliminate asparagine-glycine pairs, which form potential deamidation sites, by altering one or both of the residues. This is 5 preferably done in framework regions, the constant domain or non-canonical regions of the antibody.
- an anti-CD40 antibody that is an activating antibody, i.e., a CD40 agonist.
- An activating antibody 0 amplifies or substitutes for the effects of CD40L on CD40.
- the activating antibody is essentially a mimic of CD40L, and competes with CD40L for binding to CD40.
- the antibody does not compete with CD40L for binding to CD40, but amplifies the effect of CD40L binding to CD40.
- the anti-CD40 antibody activates CD40 in the presence or absence of CD40L.
- the invention provides an anti-CD40 antibody that inhibits the proliferation of tumor cells in vitro or tumor growth in vivo.
- the antibody inhibits tumor growth by at least 50%, 55%, 60%, 65%, 70%, 75%. In some embodiments, the antibody inhibits tumor growth by 75%. In one embodiment, the inhibition of tumor growth is detectable 14 days after initial treatment with the antibody. In other embodiments, the inhibition of tumor growth is detectable 7 days after initial treatment with the antibody.
- another antineoplastic agent is administered to the animal with the anti-CD40 antibody. In some embodiments, the antineoplastic agent further inhibits tumor growth. In some embodiments, the antineoplastic agent is adriamycin or taxol. In some embodiments, the co-admimstration of an antineoplastic agent and the anti-CD40 antibody inhibits tumor growth by at least 50%, after a period of 22-24 days from initiation of treatment compared to tumor growth on an untreated animal.
- Another aspect of the invention provides an anti-CD40 antibody that induces cell death of CD40 positive cells.
- the antibody causes apoptosis of CD40 positive cells either in vivo or in vitro.
- the anti-CD40 antibody enhances the expression of B cell surface molecules, including but not limited to ICAM, MHC-II, B7-2, CD71, CD23 and CD83.
- 1 ⁇ g/ml of the antibody enhances ICAM expression in a whole blood B-cell surface molecule up-regulation assay by at least 2 fold, or more preferably by at least 4 fold.
- 1 ⁇ g/ml of the antibody enhances MHC-II expression in a whole blood B-cell surface molecule upregulation assay by at least 2 fold, or more preferably by at least 3 fold.
- 1 ⁇ g ml of the antibody enhances CD23 expression in whole blood B-cell surface molecule up-regulation assay by at least 2 fold, or more preferably by at least 5 fold. See, e.g., Example VII, Table 25.
- the anti-CD40 antibody enhances the expression of dendritic cell surface molecules including but not limited to MHC-II, ICAM, B7-2, CD83 and B7-1.
- the range of upregulation is similar to the range of upregulation observed in B cells. See, e.g., Tables 25 and 26, infra.
- the antibody preferentially upregulates the expression of dendritic cell surface molecules, such as B7-2 and MHC-II, compared to B cell expression of these molecules. See, e.g., Table 27.
- the antibody enhances cellular secretion of cytokines including but not limited to IL-8, IL-12, IL-15, IL-18 and IL-23. [0132] In some embodiments the antibody enhances cytokine secretion by dendritic cells and adherent monocytes. In some embodiments cytokine production is further enhanced by co-stimulation with one or more of LPS, IFN- ⁇ or IL-ljS. In yet another aspect of the invention, the antibody with LPS co- stimulation enhances IL-12p70 production in a dendritic cell assay with an EC 50 of about 0.48 ⁇ g/ml. In some embodiments, the antibody enhances IL-12p40 production in dendritic cells with an EC 50 of about 0.21 ⁇ g/ml. (See, e.g., Example
- the antibody enhances secretion of IFN-gamma by
- the antibody enhances IFN-gamma secretion in an allogenic T cell dendritic cell assay with an EC 50 of about 0.3 ⁇ g/ml. In some embodiments, the antibody enhances IFN-gamma secretion in an allogenic T cel .dendritic cell assay with an EC50 of about 0.2 ⁇ g/ml. In one embodiment, the antibody enhances IFN-gamma secretion in an allogenic T cell/dendritic cell assay with an EC 50 of about 0.03 ⁇ g/ml.
- human antibodies are produced by immunizing a non-human animal comprising in its genome some or all of human immunoglobulin heavy chain and light chain loci with a CD40 antigen.
- the non-human animal is a XenoMouseTM animal.
- XenoMouseTM mice are engineered mouse strains that comprise large fragments of human immunoglobulin heavy chain and light chain loci and are deficient in mouse antibody production. See, e.g., Green et al., Nature Genetics 7:13-21 (1994) and U.S. Patents 5,916,771, 5,939,598, 5,985,615, 5,998,209,
- the invention provides a method for making anti-CD40 antibodies from non-human, non-mouse animals by immunizing non-human transgenic animals that comprise human immunoglobulin loci with a CD40 antigen.
- the non-human animals are rats, sheep, pigs, goats, cattle or horses.
- XenoMouseTM mice produce an adult-like human repertoire of fully human antibodies and generate antigen-specific human antibodies.
- the XenoMouseTM mice contain approximately 80% of the human antibody V gene repertoire through introduction of megabase sized, germline configuration yeast artificial chromosome (YAC) fragments of the human heavy chain loci and kappa light chain loci.
- YAC yeast artificial chromosome
- the non-human animal comprising human immunoglobulin genes are animals that have a human immunoglobulin "minilocus".
- minilocus an exogenous Ig locus is mimicked through the inclusion of individual genes from the Ig locus.
- one or more N H genes, one or more D H genes, one or more J H genes, a mu constant domain, and a second constant domain (preferably a gamma constant domain) are formed into a construct for insertion into an animal.
- This approach is described, inter alia, in U.S. Patent os. 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425,
- An advantage of the minilocus approach is the rapidity with which constructs including portions of the Ig locus can be generated and introduced into animals.
- a potential disadvantage of the minilocus approach is that there may not be sufficient immunoglobulin diversity to support full B-cell development, such that there may be lower antibody production.
- the invention provides a method for making humanized anti-CD40 antibodies.
- non-human animals are immunized with a CD40 antigen as described below under conditions that permit antibody production.
- Antibody-producing cells are isolated from the animals, fused with myelomas to produce hybridomas, and nucleic acids encoding the heavy and light chains of an anti-CD40 antibody of interest are isolated. These nucleic acids are subsequently engineered using techniques known to those of skill in the art and as described further below to reduce the amount of non-human sequence, i.e., to humanize the antibody to reduce the immune response in humans [0141]
- the CD40 antigen is isolated and/or purified CD40.
- the CD40 antigen is human CD40.
- the CD40 antigen is a fragment of CD40.
- the CD40 fragment is the extracellular domain of CD40.
- the CD40 fragment comprises at least one epitope of CD40.
- the CD40 antigen is a cell that expresses or overexpresses CD40 or an immunogenic fragment thereof on its surface.
- the CD40 antigen is a CD40 fusion protein.
- the CD40 antigen is administered with an adjuvant to stimulate the immune response.
- adjuvants include complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes).
- RIBI muramyl dipeptides
- ISCOM immunocomplementary metal-oxide-semiconductor
- antibodies and/or antibody-producing cells can be obtained from the animal.
- anti-CD40 antibody-containing serum is obtained from the animal by bleeding or sacrificing the animal.
- the serum may be used as it is obtained from the animal, an immunoglobulin fraction may be obtained from the serum, or the anti-CD40 antibodies may be purified from the serum.
- serum or immunoglobulins obtained in this manner will be polyclonal
- the disadvantage is using polyclonal antibodies prepared from serum is that the amount of antibodies that can be obtained is limited and the polyclonal antibody has a heterogeneous anay of properties.
- antibody-producing immortalized cell lines are prepared from cells isolated from the immunized animal. After immunization, the animal is sacrificed and lymph node and/or splenic B cells are immortalized.
- Methods of immortalizing cells include, but are not limited to, transferring them with oncogenes, inflecting them with the oncogenic virus cultivating them under conditions that select for immortalized cells, subjecting them to carcinogenic or mutating compounds, fusing them with an immortalized cell, e.g., a myeloma cell, and inactivating a tumor suppressor gene. See, e.g., Harlow and Lane, supra.
- the myeloma cells preferably do not secrete immunoglobulin polypeptides (a non-secretory cell line).
- Immortalized cells are screened using CD40, a portion thereof, or a cell expressing CD40.
- the initial screening is performed using an enzyme-linked immunoassay (ELISA) or a radioimmunoassay.
- ELISA enzyme-linked immunoassay
- radioimmunoassay An example of ELISA screening is provided in WO 00/37504, herein incorporated by reference.
- Anti-CD40 antibody-producing cells e.g., hybridomas
- Hybridomas can be expanded in vivo in syngeneic animals, in animals that lack an immune system, e.g., nude mice, or in cell culture in vitro.
- the immunized animal is a non-human animal that expresses human immunoglobulin genes and the splenic B cells are fused to a myeloma cell line from the same species as the non-human animal.
- the immunized animal is a XENOMOUSETM animal and the myeloma cell line is a non-secretory mouse myeloma.
- the myeloma cell line is P3-X63-AG8.653. See, e.g., Example I.
- the invention provides hybridomas that produce an human anti-CD40 antibody.
- the hybridomas are mouse hybridomas, as described above.
- the hybridomas are produced in a non-human, non-mouse species such as rats, sheep, pigs, goats, cattle or horses.
- the hybridomas are human hybridomas.
- the present invention also encompasses nucleic acid molecules encoding anti-CD40 antibodies.
- different nucleic acid molecules encode a heavy chain and a light chain of an anti-CD40 immunoglobulin.
- the same nucleic acid molecule encodes a heavy chain and a light chain of an anti-CD40 immunoglobulin.
- the nucleic acid molecule encoding the variable domain of the light chain comprises a human A3/A19 (DPK-15), L5 (DP5) or A27 (DPK-22) V/c gene sequence or a sequence derived therefrom.
- the nucleic acid molecule comprises a nucleotide sequence of a A3/A19 V/c gene and a J/cl, Jc2 or Jc3 gene or sequences derived therefrom. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence of an L5 V c gene and a J/c4 gene. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence of a A27 V/c gene and a J ⁇ 3 gene. [0151] In some embodiments, the nucleic acid molecule encoding the light chain, encodes an amino acid sequence comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mutations from the germline amino acid sequence.
- the nucleic acid molecule comprises a nucleotide sequence that encodes a VL amino acid sequence comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 non-conservative amino acid substitutions and/or 1, 2 or 3 non-conservative substitutions compared to the germline sequence. Substitutions may be in the CDR regions, the framework regions or in the constant domain.
- the nucleic acid molecule encoding the variable domain of the light chain (V L ) encodes a V L amino acid sequence comprising one or more mutations compared to the germline sequence that are identical to the mutations found in the V L of one of the antibodies 3.1.1, 3.1.1L-L4M-L83V, 7.1.2,
- the nucleic acid molecule encodes at least three amino acid mutations compared to the germline sequence found in the V of one of the antibodies 3.1.1, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1, 23.28.1L-C92A, 23.29.1 and 24.2.1.
- the nucleic acid molecule comprises a nucleotide sequence that encodes the V L amino acid sequence of monoclonal antibody 3.1.1 (SEQ ID NO: 4), 3.1.1L-L4M-L83V (SEQ ID NO: 94), 7.1.2 (SEQ'ID NO: 12), 10.8.3 (SEQ ID NO: 20), 15.1.1 (SEQ ID NO: 28), 21.2.1 (SEQ ID NO: 36), 2.1.4.1 (SEQ ID NO: 44), 22.1.1 (SEQ ID NO: 52), 23.5.1 (SEQ ID NO: 60),
- said portion comprises at least the CDR3 region.
- the nucleic acid encodes the amino acid sequence of the light chain CDRs of said antibody.
- said portion is a contiguous portion comprising CDR1-CDR3.
- the nucleic acid molecule comprises a nucleotide sequence that encodes the amino acid sequence of one of SEQ ID NOS: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94 or 100, or said sequence lacking the signal sequence.
- the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NOS: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, 93 or 99, or a portion thereof, said sequences optionally lacking the signal sequence.
- said portion encodes a V L region. In some embodiments, said portion encodes at least the CDR2 region. In some embodiments, the nucleic acid encodes the amino acid sequence of the light chain CDRs of said antibody. In some embodiments, said portion encodes a contiguous region from CDR1-CDR3.
- the nucleic acid molecule encodes a V L amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to a V L amino acid sequence of any one of antibodies 3.1.1, 3.1.1L-L4M- L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1,
- Nucleic acid molecules of the invention include nucleic acids that hybridize under highly stringent conditions, such as those described above, to a nucleic acid sequence encoding the amino acid sequence of SEQ ID NOS: 4, 12, 20, 28, 36, 44, 52, 60,
- the nucleic acid encodes a full-length light chain of an antibody selected from 3.1.1, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 23.5.1, 23.25.1, 23.28.1, 23.28.1L-C92A, 23.29.1, 23.29.1L-
- nucleic acid may comprise the nucleotide sequence of SEQ ID NOS: 7, 15, 23, 31, 39, 47, 55, 63, 71, 79 or 87, or a nucleic acid molecule encoding a light chain comprise a mutation, such as one disclosed herein.
- the nucleic acid molecule encodes the variable domain of the heavy chain (V H ) that comprises a human 3-30+, 4-59, 1- 02, 4.35 or 3-30.3 V H gene sequence or a sequence derived therefrom.
- V H variable domain of the heavy chain
- the nucleic acid molecule comprises a human 3-30+ V H gene, a D4 (DIR3) gene and a human J H 6 gene; a human 3-30+ VH gene, a human Dl-26 (DIR5) gene and a human J H 6 gene; a human 4.35 V H gene, a human DIR3 gene and a human H 6 gene; a human 4-59 V H gene, a human D4-23 gene and a human J H 4 gene; a human 1-02 V H gene, a human DLR1 gene and a human J H 4 gene; a human 3-30+ V H gene, a human D6-19 (DIR3) gene and a human J H 4 gene; a human 3-30+ VH gene, a human Dl-1 gene and a human J H 6 gene; a human 3-30+ V H gene, a human D4-17 gene and a human J H 6 gene; a human 3-30.3 VH gene, a human D4-17 gene and a human JH6 gene;
- the nucleic acid molecule encodes an amino acid sequence comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 mutations compared to the germline amino acid sequence of the human V, D or J genes.
- said mutations are in the V H region.
- said mutations are in the CDR regions.
- the nucleic acid molecule encodes one or more amino acid mutations compared to the germline sequence that are identical to amino acid mutations found in the V H of monoclonal antibody 3.1.1, 3.1.1 H-A78T,
- the nucleic acid encodes at least three amino acid mutations compared to the germline sequences that are identical to at least three amino acid mutations found in one of the above-listed monoclonal antibodies.
- the nucleic acid molecule comprises a nucleotide sequence that encodes at least a portion of the V H amino acid sequence of antibody 3.1.1 (SEQ ID NO: 2), 3.1.1H-A78T (SEQ ID NO: 90), 3.1.1H-A78T-V88A- V97A (SEQ ID NO: 92), 7.1.2 (SEQ ID NO: 10), 10.8.3 (SEQ ID NO: 18), 15.1.1 (SEQ ID NO: 26), 21.2.1 (SEQ ID NO: 34), 21.4.1 (SEQ ID NO: 42), 22.1.1 (SEQ ID NO: 50), 22.1.1H-C109A (SEQ ID NO: 96), 23.5.1 (SEQ ID NO: 58), 23.28.1 (SEQ ID NO: 66), 23.28.1H-D16E (SEQ ID NO: 98), 23.29.1 (SEQ ID NO: 74) or 24.2.1 (SEQ ID NO: 82), or said sequence having conservative amino acid mutations and/or a
- the sequence encodes one or more CDR regions, preferably a CDR3 region, all three CDR regions, a contiguous portion including CDR1-CDR3, or the entire V H region, with or without a signal sequence.
- the nucleic acid molecule comprises a nucleotide sequence that encodes the amino acid sequence of one of SEQ ID NOS: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98, or said sequence lacking the signal sequence.
- the nucleic acid molecule comprises at least aportion of the nucleotide sequence of SEQ ID NO: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89, 91, 95 or 97, or said sequence lacking the signal sequence.
- said portion encodes the V H region (with or without a signal sequence), a CDR3 region, all three CDR regions, or a contiguous region including CDR1-CDR3.
- the nucleic acid molecule encodes a V H amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the V H amino acid sequences shown in FIGS.
- Nucleic acid molecules of the invention include nucleic acids that hybridize under highly stringent conditions, such as those described above, to a nucleic acid sequence encoding the amino acid sequence of SEQ ID NOS: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96 or 98, or that has the nucleic acid sequence of SEQ ID NOS: 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89, 91, 95 or 97.
- Nucleic acid molecule of the invention include nucleic acid molecule that hybridize under highly stringent conditions, such as those described above, to a nucleic acid sequence encoding a V H described immediately above.
- the nucleic acid encodes a full-length heavy chain of an antibody selected from 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-V88A- V97A, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.29.1 and 24.2.1, or a heavy chain having the amino acid sequence of SEQ ID NOS: 6, 14, 22, 30, 38, 46, 54, 62, 70, 78 or 86, or a heavy chain comprising a mutation, such as one of the mutations discussed herein Further, the nucleic acid may comprise the nucleotide sequence of SEQ ID NOS: 5, 13, 21, 29, 37, 45
- a nucleic acid molecule encoding the heavy or entire light chain of an anti-CD40 antibody or portions thereof can be isolated from any source that produces such antibody.
- the nucleic acid molecules are isolated from a B cell isolated from an animal immunized with CD40 or from an immortalized cell derived from such a B cell that expresses an anti-CD40 antibody.
- Methods of isolating mRNA encoding an antibody are well-known in the art. See, e.g., Sambrook et al. The mRNA may be used to produce cDNA for use in the polymerase chain reaction (PCR) or cDNA cloning of antibody genes.
- the nucleic acid molecule is isolated from a hybridoma that has as one of its fusion partners a human immunoglobulin-producing cell from a non-human transgenic animal.
- the human immunoglobulin producing cell is isolated from a XenoMouse animal.
- the human immunoglobulin-producing cell is from a non- human, non-mouse transgenic animal, as described above.
- the nucleic acid is isolated from a non-human, non-transgenic animal
- the nucleic acid molecules isolated from a non-human, non-transgenic animal may be used, e.g., for humanized antibodies.
- a nucleic acid encoding a heavy chain of an anti- CD40 antibody of the invention can comprise a nucleotide sequence encoding a V H domain of the invention joined in-frame to a nucleotide sequence encoding a heavy chain constant domain from any source.
- a nucleic acid molecule encoding a light chain of an anti-CD40 antibody of the invention can comprise a nucleotide sequence encoding a V L domain of the invention joined in-frame to a nucleotide sequence encoding a light chain constant domain from any source.
- nucleic acid molecules encoding the variable domain of the heavy (V H ) and light (V L ) chains are "converted" to full- length antibody genes.
- nucleic acid molecules encoding the VH or V L domains are converted to full-length antibody genes by insertion into an expression vector already encoding heavy chain constant or light chain constant domains, respectively, such that the V H segment is operatively linked to the CH segment(s) within the vector, and the VL segment is operatively linked to the CL segment within the vector.
- nucleic acid molecules encoding the VH and/or V L domains are converted into full-length antibody genes by linking, e.g., ligating, a nucleic acid molecule encoding a VH and/or VL domains to a nucleic acid molecule encoding a CH and/or CL domain using standard molecular biological techniques.
- Nucleic acid sequences of human heavy and light chain immunoglobulin constant domain genes are known in the art. See, e.g.,
- nucleic acid molecules encoding the full-length heavy and/or light chains may then be expressed from a cell into which they have been introduced and the anti-CD40 antibody isolated.
- the nucleic acid molecules may be used to recombinantly express large quantities of anti-CD40 antibodies.
- the nucleic acid molecules also may be used to produce chimeric antibodies, bispecific antibodies, single chain antibodies, immunoadhesins, diabodies, mutated antibodies and antibody derivatives, as described further below. If the nucleic acid molecules are derived from a non- human, non-transgenic animal, the nucleic acid molecules may be used for antibody humanization, also as described below.
- a nucleic acid molecule of the invention is used as a probe or PCR primer for a specific antibody sequence.
- the nucleic acid can be used as a probe in diagnostic methods or as a PCR primer to amplify regions of DNA that could be used, inter alia, to isolate additional nucleic acid molecules encoding variable domains of anti-CD40 antibodies.
- the nucleic acid molecules are oligonucleotides.
- the oligonucleotides are from highly variable regions of the heavy and light chains of the antibody of interest, hi some embodiments, the oligonucleotides encode all or a part of one or more of the CDRs of antibody 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-V88A-V97A, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H- D16E, 23.28.1L-C92A, 23.29.1 or 24.2.1.
- the invention provides vectors comprising nucleic acid molecules that encode the heavy chain of an anti-CD40 antibody of the invention or an antigen- binding portion thereof.
- the invention also provides vectors comprising nucleic acid molecules that encode the light chain of such antibodies or antigen-binding portion thereof.
- the invention further provides vectors comprising nucleic acid molecules encoding fusion proteins, modified antibodies, antibody fragments, and probes thereof.
- the anti-CD40 antibodies, or antigen-binding portions of the invention are expressed by inserting D ⁇ As encoding partial or full-length light and heavy chains, obtained as described above, into expression vectors such that the genes are operatively linked to necessary expression control sequences such as transcriptional and translational control sequences.
- Expression vectors include plasmids, retroviruses, adenovirases, adeno-associated viruses (AAN), plant viruses such as cauliflower mosaic virus, tobacco mosaic virus, cosmids, YACs, EBN derived episomes, and the like.
- the antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the antibody gene.
- the expression vector and expression control sequences are chosen to be compatible with the expression host cell used.
- the antibody light chain gene and the antibody heavy chain gene can be inserted into separate vectors. In a prefened embodiment, both genes are inserted into the same expression vector.
- a convenient vector is one that encodes a functionally complete human C H or C L immunoglobulin sequence, with appropriate restriction sites engineered so that any N ⁇ or N L sequence can easily be inserted and expressed, as described above.
- splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C domain, and also at the splice regions that occur within the human C H exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions.
- the recombinant expression vector also can encode a signal peptide that facilitates secretion of the antibody chain from a host cell.
- the antibody chain gene may be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the immunoglobulin chain.
- the signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein).
- the recombinant expression vectors of the invention cany regulatory sequences that control the expression of the antibody chain genes in a host cell.
- Prefened regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from retroviral LTRs, cytomegalovirus (CMN) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)), polyoma and strong mammalian promoters such as native immunoglobulin and actin promoters.
- CCN cytomegalovirus
- SV40 Simian Virus 40
- AdMLP adenovirus major late promoter
- the recombinant expression vectors of the invention may cany additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes.
- the selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Patent Nos. 4,399,216, 4,634,665 and 5,179,017).
- the selectable marker gene confers resistance to drags, such as G418, hygromycin or methofrexate, on a host cell into which the vector has been introduced.
- Prefened selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr-host cells with methofrexate selection/amplification), the neo gene (for G418 selection), and the glutamate synthetase gene.
- DHFR dihydrofolate reductase
- neo gene for G418 selection
- glutamate synthetase gene for use in dhfr-host cells with methofrexate selection/amplification
- Nucleic acid molecules encoding anti-CD40 antibodies and vectors comprising these nucleic acid molecules can be used for transfection of a suitable mammalian, plant, bacterial or yeast host cell. Transformation can be by any known method for introducing polynucleotides into a host cell.
- Methods for introduction of heterologous polynucleotides into mammalian cells include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
- nucleic acid molecules may be introduced into mammalian cells by viral vectors.
- Methods of transforming cells are well known in the art. See, e.g., U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference). Methods of transforming plant cells are well known in the art, including, e.g.,
- Agrobacterium-mediated transformation biolistic transformation, direct injection, electroporation and viral transformation.
- Methods of transforming b # acterial and yeast cells are also well known in the art.
- Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type
- ATCC Culture Collection
- CHO Chinese hamster ovary
- NSO Chinese hamster ovary
- SP2 cells
- HeLa cells
- BHK baby hamster kidney
- COS monkey kidney cells
- human hepatocellular carcinoma cells e.g., Hep G2
- A549 cells A549 cells
- cell lines of particular preference are selected through determining which cell lines have high expression levels.
- Other cell lines that may be used are insect cell lines, such as Sf9 cells.
- the antibodies When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or, more preferably, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification methods.
- Plant host cells include, e.g., Nicotiana, Arabidopsis, duckweed, corn, wheat, potato, etc.
- Bacterial host cells include E. coli and Streptomyces species.
- Yeast host cells include Schizosaccharomyces pombe, Saccharomyces cerevisiae and Pichia pastoris.
- GS system glutamine synthetase gene expression system
- Anti-CD40 antibodies of the invention also can be produced transgenically through the generation of a mammal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom.
- anti-CD40 antibodies can be produced in, and recovered from, the milk of goats, cows, or other mammals. See, e.g., U.S. Patent Nos. 5,827,690, 5,756,687, 5,750,172, and 5,741,957.
- non- human transgenic animals that comprise human immunoglobulin loci are immunized with CD40 or an immunogenic portion thereof, as described above. Methods for making antibodies in plants are described, e.g., in US patents 6,046,037 and US 5,959,177.
- non-human transgenic animals or plants are produced by introducing one or more nucleic acid molecules encoding an anti- CD40 antibody of the invention into the animal or plant by standard transgenic techniques. See Hogan and United States Patent 6,417,429, supra.
- the transgenic cells used for making the transgenic animal can be embryonic stem cells or somatic cells.
- the transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes.
- the transgenic non-human animals have a targeted disruption and replacement by a targeting construct that encodes a heavy chain and/or a light chain of interest.
- the transgenic animals comprise and express nucleic acid molecules encoding heavy and light chains that specifically bind to CD40, preferably human CD40.
- the transgenic animals comprise nucleic acid molecules encoding a modified antibody such as a single-chain antibody, a chimeric antibody or a humanized antibody.
- the anti- CD40 antibodies may be made in any transgenic animal.
- the non-human animals are mice, rats, sheep, pigs, goats, cattle or horses.
- the non-human transgenic animal expresses said encoded polypeptides in blood, milk, urine, saliva, tears, mucus and other bodily fluids.
- the invention provides a method for producing an anti-CD40 antibody or antigen-binding portion thereof comprising the steps of synthesizing a library of human antibodies on phage, screening the library with CD40 or a portion thereof, isolating phage that bind CD40, and obtaining the antibody from the phage.
- one method for preparing the library of antibodies for use in phage display techniques comprises the steps of immunizing a non-human animal comprising human immunoglobulin loci with CD40 or an antigenic portion thereof to create an immune response, extracting antibody producing cells from the immunized animal; isolating RNA from the extracted cells, reverse transcribing the RNA to produce cDNA, amplifying the cDNA using a primer, and inserting the cDNA into a phage display vector such that antibodies are expressed on the phage.
- Recombinant anti-CD40 antibodies of the invention may be obtained in this way.
- Recombinant anti-CD40 human antibodies of the invention can be isolated by screening a recombinant combinatorial antibody library.
- the library is a scFv phage display library, generated using human N L and N ⁇ cD As prepared from mR ⁇ A isolated from B cells.
- Methodologies for preparing and screening such libraries are known in the art.
- kits for generating phage display libraries e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZAPTM phage display kit, catalog no. 240612).
- kits for generating phage display libraries e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZAPTM phage display kit, catalog no. 240612).
- methods and reagents that can be used in generating and screening antibody display libraries (see, e.g., U.S. Patent o. 5,223,409; PCT Publication Nos.
- a human anti-CD40 antibody as described herein is first used to select human heavy and light chain sequences having similar binding activity toward CD40, using the epitope imprinting methods described in PCT Publication No. WO 93/06213.
- the antibody libraries used in this method are preferably scFv libraries prepared and screened as described in PCT Publication No. WO 92/01047, McCafferty et al, Nature 348:552-554 (1990); and Griffiths et al, EMBOJ. 12:725-734 (1993).
- the scFv antibody libraries preferably are screened using human CD40 as the antigen.
- the N and N H segments of the prefened N L /N H pair(s) can be randomly mutated, preferably within the CDR3 region of N H and/or N L , in a process analogous to the in vivo somatic mutation process responsible for affinity maturation of antibodies during a natural immune response.
- This in vitro affinity maturation can be accomplished by amplifying N H and N L domains using PCR primers complimentary to the N H CDR3 or N L CDR3, respectively, which primers have been "spiked” with a random mixture of the four nucleotide bases at certain positions such that the resultant PCR products encode N H and N segments into which random mutations have been introduced into the N H and/or N L CDR3 regions. These randomly mutated N ⁇ and N L segments can be rescreened for binding to CD40.
- nucleic acids encoding the selected antibody can be recovered from the display package (e.g., from the phage genome) and subcloned into other expression vectors by standard recombinant D ⁇ A techniques. If desired, the nucleic acid can further be manipulated to create other antibody forms of the invention, as described below.
- the D ⁇ A encoding the antibody is cloned into a recombinant expression vector and introduced into a mammalian host cells, as described above.
- Another aspect of the invention provides a method for converting the class or subclass of an anti-CD40 antibody to another class or subclass.
- a nucleic acid molecule encoding a N or N ⁇ that does not include any nucleic acid sequences encoding C L or C H is isolated using methods well- known in the art.
- the nucleic acid molecule then is operatively linked to a nucleic acid sequence encoding a C L or C H from a desired immunoglobulin class or subclass. This can be achieved using a vector or nucleic acid molecule that comprises a C L or C H chain, as described above.
- an anti-CD40 antibody that was originally IgM can be class switched to an IgG.
- Another method for producing an antibody of the invention comprising a desired isotype comprises the steps of isolating a nucleic acid encoding a heavy chain of an anti-CD40 antibody and a nucleic acid encoding a light chain of an anti-CD40 antibody, isolating the sequence encoding the V H region, ligating the V H sequence to a sequence encoding a heavy chain constant domain of the desired isotype, expressing the light chain gene and the heavy chain construct in a cell, and collecting the anti-CD40 antibody with the desired isotype.
- the antibody may be deimmunized using the techniques described in, e.g., PCT Publication Nos. WO98/52976 and WO00/34317 (which incorporated herein by reference in their entirety).
- the nucleic acid molecules, vectors and host cells may be used to make mutated anti-CD40 antibodies.
- the antibodies may be mutated in the variable domains of the heavy and/or light chains, e.g., to alter a binding property of the antibody.
- a mutation may be made in one or more of the CDR regions to increase or decrease the K D of the antibody for CD40, to increase or decrease K off , or to alter the binding specificity of the antibody.
- Techniques in site-directed mutagenesis are well-known in the art. See, e.g., Sambrook et al and Ausubel et al, supra.
- mutations are made at an amino acid residue that is known to be changed compared to germline in a variable domain of an anti-CD40 antibody.
- one or more mutations are made at an amino acid residue that is known to be changed compared to the germline in a CDR region or framework region of a variable domain, or in a constant domain of a monoclonal antibody 3.1.1, 3.1.1 H- A78T, 3.1.1H-A78T-V88A-V97A, 3.1.1L-L4M-L83V, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1, 23.29.1L-R174K and 24.2.1.
- one or more mutations are made at an amino acid residue that is known to be changed compared to the germline in a CDR region or framework region of a variable domain of an amino acid sequence selected from SEQ ID NOS: 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 94, 100, 102, 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 92, 96, 98, 100 or 102, or whose nucleic acid sequence is presented in SEQ ID NOS: 3, 11, 19, 27, 35, 43, 51, 59, 67, 75, 83, 93, 99, 101, 1, 9, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89, 91, 95, 97, 99 or 101.
- the framework region is mutated so that the resulting framework region(s) have the amino acid sequence of the conesponding germline gene.
- a mutation may be made in a framework region or constant domain to increase the half-life of the anti-CD40 antibody. See, e.g., PCT Publication No. WO 00/09560, herein incorporated by reference.
- a mutation in a framework region or constant domain also can be made to alter the immunogenicity of the antibody, to provide a site for covalent or non-covalent binding to another molecule, or to alter such properties as complement fixation, FcR binding and ADCC.
- a single antibody may have mutations in any one or more of the framework regions, the constant domain and in the variable regions.
- amino acid mutations there are from 1 to 18, including any number in between, amino acid mutations in either the V H or V L domains of the mutated anti- CD40 antibody compared to the anti-CD40 antibody prior to mutation.
- the mutations may occur in one or more CDR regions.
- any of the mutations can be conservative amino acid substitutions.
- a fusion antibody or immunoadhesin may be made that comprises all or a portion of an anti-CD40 antibody of the invention linked to another polypeptide.
- only the variable domains of the anti-CD40 antibody are linked to the polypeptide.
- the V H domain of an anti-CD40 antibody is linked to a first polypeptide
- the V L domain of an anti-CD40 antibody is linked to a second polypeptide that associates with the first polypeptide in a manner such that the V H and V L domains can interact with one another to form an antibody binding site.
- the V H domain is separated from the V L domain by a linker such that the V H and V L domains can interact with one another (see below under Single Chain Antibodies).
- the V H -linker-N antibody is then linked to the polypeptide of interest.
- the fusion antibody is useful for directing a polypeptide to a CD40-ex ⁇ ressing cell or tissue.
- the polypeptide may be a therapeutic agent, such as a toxin, growth factor or other regulatory protein, or may be a diagnostic agent, such as an enzyme that may be easily visualized, such as horseradish peroxidase.
- fusion antibodies can be created in which two (or more) single-chain antibodies are linked to one another.
- the N H - and N L -encoding D ⁇ A fragments are operatively linked to another fragment encoding a flexible linker, e.g., encoding the amino acid sequence (Gly 4 -Ser) 3 , such that the N H and N L sequences can be expressed as a contiguous single-chain protein, with the N and NH domains joined by the flexible linker.
- a flexible linker e.g., encoding the amino acid sequence (Gly 4 -Ser) 3 , such that the N H and N L sequences can be expressed as a contiguous single-chain protein, with the N and NH domains joined by the flexible linker.
- the single chain antibody may be monovalent, if only a single NH and N L are used, bivalent, if two N H and N L are used, or polyvalent, if more than two N H and N L are used. Bispecific or polyvalent antibodies may be generated that bind specifically to CD40 and to another molecule.
- other modified antibodies may be prepared using anti-CD40 antibody-encoding nucleic acid molecules.
- "Kappa bodies” 111 et al, Protein Eng. 10: 949-57 (1997)
- “Minibodies” Martin et al, EMBO J. 13: 5303-9 (1994)
- “Diabodies” HoUiger et al, Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993)
- “Janusins” Traunecker et al, EMBOJ. 10:3655- 3659 (1991) and Traunecker et al, Int. J. Cancer (Suppl.) 7:51-52 (1992)
- Bispecific antibodies or antigen-binding fragments can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, Clin. Exp. Immunol. 79: 315-321 (1990), Kostelny et al, J Immunol. 148:1547-1553 (1992).
- bispecific antibodies may be formed as "diabodies" or "Janusins.” In some embodiments, the bispecific antibody binds to two different epitopes of CD40.
- the bispecific antibody has a first heavy chain and a first light chain from monoclonal antibody 3.1.1, 3.1.1H-A78T, 3.1.1H-A78T-N88A-N97A, 3.1.1L-L4M-L83N, 7.1.2, 10.8.3, 15.1.1, 21.4.1, 21.2.1, 22.1.1, 22.1.1H-C109A, 23.5.1, 23.25.1, 23.28.1, 23.28.1H-D16E, 23.28.1L-C92A, 23.29.1, 23.29.1L- R174K and 24.2.1, and an additional antibody heavy chain and light chain.
- the additional light chain and heavy chain also are from one of the above-identified monoclonal antibodies, but are different from the first heavy and light chains.
- the modified antibodies described above are prepared using one or more of the variable domains or CDR regions from a human anti-CD40 monoclonal antibody provided herein, from an amino acid sequence of said monoclonal antibody, or from a heavy chain or light chain encoded by a nucleic acid sequence encoding said monoclonal antibody.
- An anti-CD40 antibody or antigen-binding portion of the invention can be derivatized or linked to another molecule (e.g., another peptide or protein).
- another molecule e.g., another peptide or protein.
- the antibodies or portion thereof is derivatized such that the CD40 binding is not affected adversely by the derivatization or labeling. Accordingly, the antibodies and antibody portions of the invention are intended to include both intact and modified forms of the human anti-CD40 antibodies described herein.
- an antibody or antibody portion of the invention can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detection agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate associate of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
- another antibody e.g., a bispecific antibody or a diabody
- a detection agent e.g., a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate associate of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
- One type of derivatized antibody is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies).
- Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate).
- Such linkers are available from Pierce Chemical Company, Rockford, 111.
- Another type of derivatized antibody is a labeled antibody.
- Useful detection agents with which an antibody or antigen-binding portion of the invention may be derivatized include fluorescent compounds, including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors and the like.
- An antibody can also be labeled with enzymes that are useful for detection, such as horseradish peroxidase, j3-galactosidase, luciferase, alkaline phosphatase, glucose oxidase and the like.
- an antibody When an antibody is labeled with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a reaction product that can be discerned. For example, when the agent horseradish peroxidase is present, the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is detectable.
- An antibody can also be labeled with biotin, and detected through indirect measurement of avidin or streptavidin binding.
- An antibody can also be labeled with a predetermined polypeptide epitope recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags).
- labels are attached by spacer arms of various lengths to reduce potential steric hindrance.
- An anti-CD40 antibody can also be labeled with a radiolabeled amino acid.
- the radiolabel can be used for both diagnostic and therapeutic purposes. For instance, the radiolabel can be used to detect CD40-expressing tumors by x-ray or other diagnostic techniques. Further, the radiolabel can be used therapeutically as a toxin for cancerous cells or tumors. Examples of labels for polypeptides include, but are not limited to, the following radioisotopes or radionuclides — 3 H, 14 C, 15 N,
- An anti-CD40 antibody can also be derivatized with a chemical group such as polyethylene glycol (PEG), a methyl or ethyl group, or a carbohydrate group. These groups are useful to improve the biological characteristics of the antibody, e.g., to increase serum half-life or to increase tissue binding.
- the invention also relates to compositions comprising a human anti- CD40 agonist antibody for the treatment of subjects in need of immunostimulation.
- Such compositions are useful to treat, prevent, reduce the frequency of or severity of infection, including viral and bacterial infection, for treating a hyperproliferative disorder, including cancerous and pre-cancerous conditions, for treating genetic immunodeficiency conditions, such as hyper-IgM syndrome and for treating primary or combined immunodeficiency conditions, including conditions characterized by neutropenia, in a mammal, including humans.
- Subjects for treatment with agonist anti-CD40 antibody therapy include any subject in need of immune enhancement, including but not limited to the elderly and individuals who are immunosuppressed, for example due to chemotherapy.
- Hyperproliferative disorders that may be treated by an agonist anti-CD40 antibody of the invention can involve any tissue or organ and include but are not limited to brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, liver, renal, ovarian, prostate, colorectal, esophageal, gynecological, nasopharynx, or thyroid cancers, melanomas, lymphomas, leukemias or multiple myelomas.
- human agonist anti-CD40 antibodies of the invention are useful to treat carcinomas of the breast, prostate, colon and lung.
- Treatment may involve administration of one or more agonist anti-CD40 monoclonal antibodies of the invention, or antigen-binding fragments thereof, alone or with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier means any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- pharmaceutically acceptable carriers are water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- additional examples of pharmaceutically acceptable substances are wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody.
- Agonist anti-CD40 antibodies of the invention and compositions comprising them can be administered in combination with one or more other therapeutic, diagnostic or prophylactic agents. Additional therapeutic agents include other anti-neoplastic, anti-tumor, anti-angiogenic or chemotherapeutic agents. Such additional agents may be included in the same composition or administered separately. In some embodiments, one or more agonist anti-CD40 antibodies of the invention can be used as a vaccine or as adjuvants to a vaccine.
- compositions of this invention may be in a variety of forms, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
- liquid solutions e.g., injectable and infusible solutions
- dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
- the prefened form depends on the intended mode of administration and therapeutic application. Typical prefened compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans.
- the prefened mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular).
- the antibody is administered by intravenous infusion or injection.
- the antibody is administered by intramuscular or subcutaneous injection.
- Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage.
- the composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered stracture suitable to high drag concentration.
- Sterile injectable solutions can be prepared by incorporating the anti-CD40 antibody in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the prefened methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
- the antibodies of the present invention can be administered by a variety of methods known in the art, although for many therapeutic applications, the prefened route/mode of administration is subcutaneous, intramuscular, or intravenous infusion. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results.
- the antibody compositions active compound may be prepared with a carrier that will protect the antibody against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- a controlled release formulation including implants, transdermal patches, and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
- an anti-CD40 antibody of the invention can be orally administered, for example, with an inert diluent or an assimilable edible carrier.
- the compound (and other ingredients, if desired) can also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
- the anti-CD40 antibodies can be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- excipients for oral therapeutic administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.
- an anti-CD40 antibody of the invention is co-formulated with and/or co-administered with one or more additional therapeutic agents.
- agents include, without limitation, antibodies that bind other targets (e.g., antibodies that bind one or more growth factors or cytokines or their cell surface receptors, such as anti-CTL4-antibody), antineoplastic agents, antitumor agents, chemotherapeutic agents, peptide analogues that activate CD40, soluble CD40L, one or more chemical agents that activates CD40, and/or other agents known in the art that can enhance an immune response against tumor cells, e.g., IFN-jSl, IL-2, IL-8, IL-12, IL-15, IL-18, IL-23, IFN- ⁇ , and GM-CSF.
- targets e.g., antibodies that bind one or more growth factors or cytokines or their cell surface receptors, such as anti-CTL4-antibody
- antineoplastic agents e.g.,
- Agonist anti-CD40 antibodies of the invention and compositions comprising them also may be administered in combination with other therapeutic regimens, in particular in combination with radiation treatment.
- the compositions of the invention may include a "therapeutically effective amount” or a "prophylactically effective amount” of an antibody or antigen-binding portion of the invention.
- a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
- a therapeutically effective amount of the antibody or antibody portion may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
- a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
- Dosage regimens can be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus can be administered, several divided doses can be administered over time or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody or antibody portion of the invention is 0.025 to 50 mg/kg, more preferably 0.1 to 50 mg/kg, more preferably 0.1-25, 0.1 to 10 or 0.1 to 3 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated.
- kits comprising an anti- CD40 antibody or antibody portion of the invention or a composition comprising such an antibody.
- a kit may include, in addition to the antibody or composition, diagnostic or therapeutic agents.
- a kit can also include instructions for use in a diagnostic or therapeutic method.
- the kit includes the antibody or a composition comprising it and a diagnostic agent that can be used in a method described below.
- the kit includes the antibody or a composition comprising it and one or more therapeutic agents that can be used in a method described below.
- compositions for inhibiting abnormal cell growth in a mammal comprising an amount of an antibody of the invention in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together effective in inhibiting abnormal cell growth.
- chemotherapeutics are presently known in the art.
- the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti- metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, e.g. anti-androgens, and anti-angiogenesis agents.
- Anti-angiogenic agents such as MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with an anti-CD40 antibody of the invention.
- MMP-2 matrix-metalloproteinase 2
- MMP-9 matrix-metalloproteinase 9
- COX-II cyclooxygenase II
- CELEBREXTM (alecoxib), valdecoxib, and rofecoxib.
- Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26, 1998), WO
- MMP inhibitors are those that do not demonstrate arthralgia. More prefened, are those that selectively inhibit MMP-2 and/or MMP- 9 relative to the other matrix-metalloproteinases (i.e.
- MMP inhibitors useful in the present invention are AG- 3340, RO 32-3555, RS 13-0830, and the compounds recited in the following list: 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(l-hydroxycarbamoyl-cyclopentyl)- amino] -propionic acid; 3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8- oxa-bicyclo [3.2.
- a compound of the invention can also be used with signal transduction inhibitors, such as agents that can inhibit EGF-R (epidermal growth factor receptor) responses, such as EGF-R antibodies, EGF antibodies, and molecules that are EGF-R inhibitors; NEGF (vascular endothelial growth factor) inhibitors, such as NEGF receptors and molecules that can inhibit NEGF; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTI ⁇ TM (Genentech, Inc.).
- EGF-R epidermal growth factor receptor
- NEGF vascular endothelial growth factor
- erbB2 receptor inhibitors such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTI ⁇ TM (Genentech, Inc.).
- EGF-R inhibitors are described in, for example in WO 95/19970 (published July 27, 1995), WO 98/14451 (published April 9, 1998), WO 98/02434 (published January 22, 1998), and United States Patent 5,747,498 (issued May 5, 1998), and such substances can be used in the present invention as described herein.
- EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems Incorporated), ABX-EGF (Abgenix/Cell Genesys), EMD-7200 (Merck KgaA), EMD-5590 (Merck KgaA), MDX-447/H-477 (Medarex Inc. and Merck KgaA), and the compounds ZD-1834, ZD-1838 and ZD-1839 (AstraZeneca), PKI-
- VEGF inhibitors for example SU-5416 and SU-6668 (Sugen Inc.), SH- 268 (Schering), and NX-1838 (NeXstar) can also be combined with the compound of the present invention.
- VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT International Application PCT/IB99/00797 (filed May 3, 1999), in WO 95/21613 (published August 17, 1995), WO 99/61422 (published December 2, 1999), United States Patent 5,834,504 (issued November 10, 1998), WO 98/50356 (published November 12, 1998), United States Patent 5,883,113 (issued March 16, 1999), United States Patent 5,886,020 (issued March 23, 1999), United States Patent 5,792,783 (issued August 11, 1998), WO 99/10349 (published March 4, 1999), WO 97/32856
- VEGF inhibitors useful in the present invention are IM862 (Cytran Inc.); anti-VEGF monoclonal antibody of Genentech, Inc.; and angiozyme, a synthetic ribozyme from Ribozyme and Chiron. These and other VEGF inhibitors can be used in the present invention as described herein.
- ErbB2 receptor inhibitors such as GW-282974 (Glaxo Wellcome pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc.) and 2B-1 (Chiron), can furthermore be combined with the compound of the invention, for example those indicated in WO 98/02434 (published January 22, 1998), WO 99/35146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published January 22, 1998), WO 97/13760 (published April 17, 1997), WO 95/19970 (published July 27, 1995), United States Patent 5,587,458 (issued
- Anti-survival agents include anti-IGF-ER antibodies and anti-integrin agents, such as anti-integrin antibodies.
- the invention provides diagnostic methods.
- the anti- CD40 antibodies can be used to detect CD40 in a biological sample in vitro or in vivo.
- the invention provides a method for diagnosing the presence or location of an CD40-expressing tumor in a subject in need thereof, comprising the steps of injecting the antibody into the subject, determining the expression of CD40 in the subject by localizing where the antibody has bound, comparing the expression in the subject with that of a normal reference subject or standard, and diagnosing the presence or location of the tumor.
- the anti-CD40 antibodies can be used in a conventional immunoassay, including, without limitation, an ELISA, an RIA, FACS, tissue immunohistochemistry, Western blot or immunoprecipitation.
- the anti-CD40 antibodies of the invention can be used to detect CD40 from humans.
- the anti-CD40 antibodies can be used to detect CD40 from Old World primates such as cynomolgus and rhesus monkeys, chimpanzees and apes.
- the invention provides a method for detecting CD40 in a biological sample comprising contacting a biological sample with an anti-CD40 antibody of the invention and detecting the bound antibody.
- the anti-CD40 antibody is directly labeled with a detectable label.
- the anti-CD40 antibody (the first antibody) is unlabeled and a second antibody or other molecule that can bind the anti-CD40 antibody is labeled.
- a second antibody is chosen that is able to specifically bind the particular species and class of the first antibody.
- the anti-CD40 antibody is a human IgG
- the secondary antibody could be an anti-human- IgG.
- Other molecules that can bind to antibodies include, without limitation,
- Suitable labels for the antibody or secondary antibody have been disclosed supra, and include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.
- suitable enzymes include horseradish peroxidase, alkaline phosphatase, /3-galactosidase, or acetylcholinesterase;
- suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
- suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include 125 1, 131 1, 35 S or 3 H.
- CD40 can be assayed in a biological sample by a competition immunoassay utilizing CD40 standards labeled with a detectable substance and an unlabeled anti-CD40 antibody.
- a competition immunoassay utilizing CD40 standards labeled with a detectable substance and an unlabeled anti-CD40 antibody.
- the biological sample, the labeled CD40 standards and the anti-CD40 antibody are combined and the amount of labeled CD40 standard bound to the unlabeled antibody is determined.
- the amount of CD40 in the biological sample is inversely proportional to the amount of labeled CD40 standard bound to the anti-CD40 antibody.
- the anti-CD40 antibodies can be used to detect CD40 in cells in cell culture.
- the anti-CD40 antibodies are used to determine the amount of CD40 on the surface of cells that have been treated with various compounds.
- This method can be used to identify compounds that are useful to activate or inhibit CD40.
- one sample of cells is treated with a test compound for a period of time while another sample is left untreated. If the total level of CD40 is to be measured, the cells are lysed and the total CD40 level is measured using one of the immunoassays described above. The total level of CD40 in the treated versus the untreated cells is compared to determine the effect of the test compound.
- a prefened immunoassay for measuring total CD40 levels is an ELISA or
- a prefened immunoassay for determining cell surface levels of CD40 includes the steps of labeling the cell surface proteins with a detectable label, such as biotin or 125 I, immunoprecipitating the CD40 with an anti-CD40 antibody and then detecting the labeled CD40.
- Another prefened immunoassay for determining the localization of CD40, e.g., cell surface levels, is by using immunohistochemistry.
- immunoassays can be scaled up for high throughput screening in order to test a large number of compounds for either activation or inhibition of CD40.
- the anti-CD40 antibodies of the invention can also be used to determine the levels of CD40 in a tissue or in cells derived from the tissue.
- the tissue is a diseased tissue.
- the tissue is a tumor or a biopsy thereof, hi some embodiments of the method, a tissue or a biopsy thereof is excised from a patient. The tissue or biopsy is then used in an immunoassay to determine, e.g., total CD40 levels, cell surface levels of CD40 or localization of CD40 by the methods discussed above.
- the above-described diagnostic method can be used to determine whether a tumor expresses high levels of CD40, which could be indicative that the tumor is a target for treatment with anti-CD40 antibody.
- the same method can also be used to monitor the effect of the treatment with anti-CD40 antibody by detecting cell death in the tumor.
- the diagnostic method can also be used to determine whether a tissue or cell expresses insufficient levels of CD40 or activated CD40, and thus is a candidate for treatment with activating anti-CD40 antibodies, CD40L and or other therapeutic agents for increasing CD40 levels or activity.
- the antibodies of the present invention can also be used in vivo to identify tissues and organs that express CD40.
- the anti-CD40 antibodies are used to identify CD40-expressing tumors.
- One advantage of using the human anti-CD40 antibodies of the present invention is that they may safely be used in vivo without eliciting an immune response to the antibody upon administration, unlike antibodies of non-human origin or with humanized antibodies.
- the method comprises the steps of administering a detectably labeled an anti-CD40 antibody or a composition comprising them to a patient in need of such a diagnostic test and subjecting the patient to imaging analysis to determine the location of the CD40-expressing tissues.
- Imaging analysis is well known in the medical art, and includes, without limitation, x-ray analysis, magnetic resonance imaging (MRI) or computed tomography (CE).
- the antibody can be labeled with any agent suitable for in vivo imaging, for example a contrast agent, such as barium, which can be used for x-ray analysis, or a magnetic contrast agent, such as a gadolinium chelate, which can be used for MRI or CE.
- labeling agents include, without limitation, radioisotopes, such as 99 Tc.
- the anti-CD40 antibody will be unlabeled and will be imaged by administering a second antibody or other molecule that is detectable and that can bind the anti- CD40 antibody.
- a biopsy is obtained from the patient to determine whether the tissue of interest expresses CD40.
- invention provides therapeutic methods of using an anti-CD40 antibody of the invention.
- a human agonist anti-CD40 antibody of the invention can be administered to a human or to a non-human mammal that expresses a cross- reacting CD40.
- the antibody can be administered to such a non-human mammal (i.e., a primate, cynomolgus or rhesus monkey) for veterinary purposes or as an animal model of human disease.
- a non-human mammal i.e., a primate, cynomolgus or rhesus monkey
- Such animal models are useful for evaluating the therapeutic efficacy of antibodies of this invention.
- the anti-CD40 antibody is administered to a subject who suffers from primary and/or combined immunodeficiencies, including CD40- dependent immunodeficiency with Hyper-IgM syndrome, Common Variable Immunodeficiency, Braton's Agammaglobulinemia, IgG subclass deficiencies, and X-linked SCID (common gamma chain mutations).
- the anti-CD40 antibody is administered to treat a subject who is immunosuppressed, for example due to chemotherapy, or has an immune- debilitating disease, including any acquired immune deficiency disease, such as HIV.
- the anti-CD40 antibody is administered to enhance the immunity of an elderly subject.
- the anti-CD40 antibody is administered to treat a subject who has a bacterial, viral, fungal or parasitic infection.
- a human agonist anti-CD40 antibody of the invention may be administered prophylactically to a subject who, because of age, illness or general poor health is susceptible to infection to prevent or to reduce the number or severity of infections.
- the anti-CD40 antibody is administered to a subject who has a hyperproliferative disorder.
- the anti-CD40 antibody is administered to treat a subject who has a tumor, i some embodiments, the tumor is CD40 positive. In some embodiments, the tumor is a CD40 negative. The tumor can be a solid tumor or a non-solid tumor such as lymphoma. In some embodiments, an anti-CD40 antibody is administered to a patient who has a tumor that is cancerous. In some embodiments, the antibody inhibits cancer cell proliferation, inhibits or prevents an increase in tumor weight or volume, and/or causes a decrease in tumor weight or volume.
- Patients that can be treated with anti-CD40 antibodies or antibody portions of the invention include, but are not limited to, patients that have been diagnosed as having brain cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colorectal cancer, colon cancer, breast cancer, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, leukemia, myeloma, multiple myeloma, cancer of the urethr
- the antibody may be administered from three times daily to once every six months, and preferably may be admimstered via an oral, mucosal, buccal, intranasal, inhalable, intravenous, subcutaneous, intramuscular, parenteral, intratumor, transdermal or topical route.
- the antibody can also be administered continuously via a minipump.
- the antibody generally will be administered for as long as the tumor is present provided that the antibody causes the tumor or cancer to stop growing or to decrease in weight or volume.
- the dosage of antibody generally will be in the range of 0.025 to 50 mg/kg, more preferably 0.1 to 50 mg/kg, more preferably 0.1-20 mg/kg, 0.1-10 mg/kg, 0.1-5 mg/kg or even more preferable 0.1-2 mg/kg..
- the anti-CD40 antibody is administered as part of a therapeutic regimen that includes one or more additional antineoplastic drags or molecules to a patient who has a hyperproliferative disorder, such as cancer or a tumor.
- exemplary antitumor agents include, but are not limited to, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating agents, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, kinase inhibitors, matrix metalloprotease inhibitors, genetic therapeutics and anti-androgens.
- the anti-CD40 antibody is administered with an antineoplastic agent, such as adriamycin or taxol
- the anti-CD40 therapy is performed along with radiotherapy, chemotherapy, photodynamic therapy, surgery or other immunotherapy.
- the anti-CD40 antibody is administered with one or more additional antibodies.
- the anti-CD40 antibody can be administered with antibodies that are known to inhibit tumor or cancer cell proliferation. Such antibodies include, but are -not limited to, an antibody that inhibits CTLA4, erbB2 receptor, EGF-R, IGF-1R, CD20 or VEGF.
- the anti-CD40 antibody is labeled with a radiolabel, an immunotoxin or a toxin, or is a fusion protein comprising a toxic peptide.
- the anti-CD40 antibody or anti-CD40 antibody fusion protein directs the radiolabel, immunotoxin, toxin or toxic peptide to the tumor or cancer cell, hi a prefened embodiment, the radiolabel, immunotoxin, toxin or toxic peptide is internalized by the tumor or cancer cell after the anti-CD40 antibody binds to the CD40 on the surface of the cell.
- the anti-CD40 antibody can be used therapeutically to induce apoptosis of specific cells in a patient.
- the cells targeted for apoptosis are cancerous or tumor cells.
- the invention provides a method of inducing apoptosis by administering an anti-CD40 antibody to a patient in need thereof.
- the invention provides a method of administering an activating anti-CD40 antibody to a patient to increase CD40 activity.
- An anti- CD40 antibody is administered with one or more other factors that increase CD40 activity.
- factors include CD40L, and/or analogues of CD40L that activate CD40.
- the anti-CD40 antibody is administered with one or more additional immune enhancing agents, including, without limitation IFN- ⁇ l, IL-2, IL-8, IL-12, IL-15, IL-18, IL-23, IFN- ⁇ , and GM-CSF.
- additional immune enhancing agents including, without limitation IFN- ⁇ l, IL-2, IL-8, IL-12, IL-15, IL-18, IL-23, IFN- ⁇ , and GM-CSF.
- a human agonist anti-CD40 antibody of the invention is used as an adjuvant to enhance the efficacy of a vaccine.
- the anti-CD-40 antibody activates CD40 on antigen presenting cells, including B cells, dendritic cells and monocytes as well as enhancing the production of immunomodulatory molecules, such as cytokines and chemokines. The immunostimulatory effect of the antibody enhances the immune response of the vaccinated subject to the vaccine antigen.
- the invention provides a method for generating a dendritic cell vaccine for cancer or for dendritic cell immunotherapy.
- dendritic cells from a cancer patient axe cultured for 1-5 -days with tumor lysate or homogenate, tumor cells killed by inadiation or other means, or tumor specific antigens (e.g., peptides, idiotypes) and 1-10 ⁇ g ml of an anti-CD40 antibody.
- the tumor antigen-pulsed dendritic cells are re-injected into the patient to stimulate anti-tumor immune responses, particularly anti-tumor CTL responses.
- Monocyte-derived dendritic cells for use in the method can be obtained from a peripheral blood sample by culture in IL-4 and GM-CSF.
- Dendritic cells also can be derived from the bone manow of a patient by magnetic purification or sorting of CD34 positive cells, followed by culture in IL-4 and GM-CSF.
- the nucleic acid molecules of the instant invention can be administered to a patient in need thereof via gene therapy.
- the therapy may be either in vivo or ex vivo.
- nucleic acid molecules encoding both a heavy chain and a light chain are administered to a patient.
- the nucleic acid molecules are administered such that they are stably integrated into chromosomes of B cells because these cells are specialized for producing antibodies.
- precursor B cells are transfected or infected ex vivo and re-transplanted into a patient in need thereof.
- precursor B cells or other cells are infected in vivo using a virus known to infect the cell type of interest.
- Typical vectors used for gene therapy include liposomes, plasmids and viral vectors.
- Exemplary viral vectors are retroviruses, adenoviruses and adeno-associated viruses. After infection either in vivo or ex vivo, levels of antibody expression can be monitored by taking a sample from the treated patient and using any immunoassay known in the art or discussed herein.
- the gene therapy method comprises the steps of administering an isolated nucleic acid molecule encoding the heavy chain or an antigen-binding portion thereof of an anti-CD40 antibody and expressing the nucleic acid molecule.
- the gene therapy method comprises the steps of administering an isolated nucleic acid molecule encoding the light chain or an antigen-binding portion thereof of an anti-CD40 antibody and expressing the nucleic acid molecule.
- the gene therapy method comprises the steps of administering of an isolated nucleic acid molecule encoding the heavy chain or an antigen-binding portion thereof and an isolated nucleic acid molecule encoding the light chain or the antigen-binding portion thereof of an anti-CD40 antibody of the invention and expressing the nucleic acid molecules.
- the gene therapy method may also comprise the step of administering another anti-cancer agent, such as taxol or adriamycin.
- Antibodies of the invention were prepared, selected, and assayed as follows:
- CAGGTGCAGCTGGAGCAGTCIGG (SEQ ID NO: 118), in conjunction with primers specific for the human Cj2 constant region , MG-40d, 5'-GCTGAGGGAGTAGAGTCCTGAGGA-3' (SEQ ID NO: 119) or CK constant region (hcP2; as previously described in Green et al, 1994).
- MG-40d 5'-GCTGAGGGAGTAGAGTCCTGAGGA-3'
- CK constant region CK constant region
- RNA from approximately 4 X 10 6 hybridoma cells using QIAGEN RNeasy RNA isolation kit (QIAGEN).
- QIAGEN QIAGEN RNeasy RNA isolation kit
- Table 1 lists the forward amplification primers used to sequence the antibody clones.
- Table 2 sets forth the gene utilization evidenced by selected hybridoma clones of antibodies in accordance with the invention: TABLE 2
- Table A provides the sequence identifiers for each of the nucleotide and predicted amino acid sequences of the sequenced antibodies.
- Tables 3-7 provide the nucleotide and predicted amino acid sequences of the heavy and kappa light chains of antibodies 3.1.1 (Table 3), 7.1.2 (Table 4), 10.8.3 (Table 5), 15.1.1 (Table 6) and 21.4.1 (Table 7).
- Tables 8-13 provide the nucleotide and predicted amino acid sequences of the variable domain of the heavy chain and kappa light chain of antibodies 21.2.1 (Table 8), 22.1.1 (Table 9), 23.5.1 (Table 10), 23.28.1 (Table 11), 23.29.1 (Table 12) and 24.2.1 (Table l3).
- the DNA sequence from the full-length sequencing of monoclonal antibody 23.28.1 differs from DNA sequences obtained from sequencing the NH region of the initial PCR product by one base pair (C to G), resulting in a change of residue 16 of the natural heavy chain from D to E.
- Tables 14-19 provide the nucleotide and predicted amino acid sequences of the heavy and kappa light chains of antibodies 21.2.1 (Table 14), 22.1.1 (Table 15), 23.5.1 (Table 16), 23.28.1 (Table 17), 23.29.1 (Table 18) and 24.2.1 (Table 19).
- the signal peptide sequence (or the bases encoding the same) are underlined.
- Table 20 provides the nucleotide and amino acid sequences of the mutated heavy chain of antibody 22.1.1H-C109A.
- Table 21 provides the nucleotide and amino acid sequences of the mutated light chain of antibody 23.28.1. The mutated D ⁇ A codons are shown in italics. The mutated amino acid residue is in bold.
- Table 3 DNA and protein sequences of antibody 3.1.1
- VYACEVTHQGLSSPVTKSF ⁇ RGEC Table 4 DNA and protein sequences of antibody 7.1.2
- Table 8 DNA and protein sequences of mature variable domains of 21.2.1 antibody
- Table 10 DNA and protein sequences of mature variable domains of 23.5.1 antibody
- Table 12 DNA and protein sequences of mature variable domains of 23.29.1 antibody
- Table 13 DNA and protein sequences of mature variable domains of 24.2.1 antibody
- Table 18 DNA and protein sequences of antibody 23.29.1
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ533180A NZ533180A (en) | 2001-11-09 | 2002-11-08 | A monoclonal antibody or antigen binding portion that specifically binds to and activates human CD40 |
APAP/P/2004/003034A AP1918A (en) | 2001-11-09 | 2002-11-08 | Antibodies to CD40 |
EA200400654A EA011449B1 (en) | 2001-11-09 | 2002-11-08 | Human monoclonal antibodies to cd40 and methods for use thereof |
AU2002356926A AU2002356926B2 (en) | 2001-11-09 | 2002-11-08 | Antibodies to CD40 |
JP2003542215A JP4616555B2 (en) | 2001-11-09 | 2002-11-08 | Antibody against CD40 |
CA2466128A CA2466128C (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
BRPI0214137A BRPI0214137B8 (en) | 2001-11-09 | 2002-11-08 | human monoclonal antibody or antigen-binding portion thereof that specifically binds to and activates human cd40, isolated hybridoma cell line, pharmaceutical composition comprising the same, use thereof in the manufacture of a drug and method of manufacturing said antibodies or antigen-binding portion of it |
DK02802898.3T DK1476185T3 (en) | 2001-11-09 | 2002-11-08 | Antibodies to CD40 |
SI200231036T SI1476185T1 (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
ES02802898T ES2432968T3 (en) | 2001-11-09 | 2002-11-08 | Antibodies against CD40 |
HU0402247A HU229829B1 (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
CN028245709A CN1582165B (en) | 2001-11-09 | 2002-11-08 | Antibodies to CD40 |
IL16182302A IL161823A0 (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 and pharmaceutical compositionscontaining the same |
MEP-2008-814A ME00503B (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
EP02802898.3A EP1476185B1 (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
MXPA04004467A MXPA04004467A (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40. |
YU39204A RS52484B (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
TNP2004000078A TNSN04078A1 (en) | 2001-11-09 | 2004-05-05 | ANTIBODIES TO CD40 |
IL161823A IL161823A (en) | 2001-11-09 | 2004-05-06 | Antibodies to cd40 and pharmaceutical compositions containing the same |
IS7253A IS2940B (en) | 2001-11-09 | 2004-05-06 | Antibodies against CD40 |
ZA2004/04207A ZA200404207B (en) | 2001-11-09 | 2004-05-28 | Antibodies to cd40 |
HRP20040525AA HRP20040525B1 (en) | 2001-11-09 | 2004-06-08 | Antibodies to cd40 |
NO20042388A NO334339B1 (en) | 2001-11-09 | 2004-06-08 | Antibody to CD40 |
HK05102440.7A HK1069122A1 (en) | 2001-11-09 | 2005-03-22 | Antibodies to cd40 cd40 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34898001P | 2001-11-09 | 2001-11-09 | |
US60/348,980 | 2001-11-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003040170A2 WO2003040170A2 (en) | 2003-05-15 |
WO2003040170A3 WO2003040170A3 (en) | 2003-10-09 |
WO2003040170A9 true WO2003040170A9 (en) | 2004-06-10 |
Family
ID=23370387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036107 WO2003040170A2 (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
Country Status (47)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US9221915B2 (en) | 2005-09-07 | 2015-12-29 | Pfizer Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
USRE45847E1 (en) | 2004-01-09 | 2016-01-19 | Pfizer Inc. | Antibodies to MAdCAM |
Families Citing this family (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244827B2 (en) * | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
US6943235B1 (en) * | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
US20050255106A1 (en) * | 1999-05-22 | 2005-11-17 | Linda Diehl | Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
WO2002020619A2 (en) | 2000-09-07 | 2002-03-14 | Schreiber John R | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
PT1391464E (en) | 2001-04-27 | 2007-11-15 | Kirin Pharma Kk | Anti-cd40 monoclonal antibody |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
WO2003045318A2 (en) * | 2001-11-21 | 2003-06-05 | Celltech R & D, Inc. | Manipulation of cytokine levels using cd83 gene products |
ATE546150T1 (en) * | 2002-06-07 | 2012-03-15 | Zymogenetics Inc | USE OF IL-21 AND MONOCLONAL ANTIBODIES TO TREAT SOLID TUMORS |
US7052694B2 (en) * | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
EP1680140B1 (en) * | 2003-10-16 | 2011-04-20 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
DK1694360T3 (en) * | 2003-11-04 | 2010-10-18 | Novartis Vaccines & Diagnostic | Use of antagonist anti-CD40 antibodies to treat autoimmune and inflammatory diseases and organ transplant rejection |
US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
CA2548015A1 (en) | 2003-12-05 | 2005-06-23 | John R. Schreiber | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
PL1707627T3 (en) | 2003-12-25 | 2013-04-30 | Kyowa Hakko Kirin Co Ltd | Antagonistic anti-CD40 antibody mutant |
NZ550518A (en) | 2004-03-23 | 2009-11-27 | Biogen Idec Inc | Agents that cross link TNF receptors for treating cancer |
US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
JP5902367B2 (en) * | 2004-06-30 | 2016-04-13 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | antibody |
CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
US20070286855A1 (en) * | 2004-08-03 | 2007-12-13 | Mayo Foundation For Medical Education And Research | Improving treatments |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
DK1836225T3 (en) | 2005-01-06 | 2012-02-27 | Innate Pharma Sas | Kir-binding agents and methods for using them |
US8716451B2 (en) | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
CA2602375C (en) * | 2005-03-23 | 2018-07-24 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
EP2444421A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
ES2429564T3 (en) * | 2005-05-18 | 2013-11-15 | Novartis Ag | Procedures for the diagnosis and treatment of diseases that have an autoimmune and / or inflammatory component |
US8337851B2 (en) * | 2005-05-18 | 2012-12-25 | Novartis Ag | Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer |
GB0512225D0 (en) * | 2005-06-16 | 2005-07-27 | Univ Sheffield | Immunoglobulin molecules |
AU2006269940C1 (en) | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
AU2007248628B2 (en) | 2006-05-03 | 2013-02-07 | The Regents Of The University Of Colorado, A Body Corporate | CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
JP4383525B2 (en) | 2006-05-09 | 2009-12-16 | ファイザー・プロダクツ・インク | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
EP1854810A1 (en) * | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
WO2007131575A1 (en) | 2006-05-12 | 2007-11-22 | Fondazione Centro San Raffaele Del Monte Tabor | Tolerogenic dendritic cells, method for their production and uses thereof |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
WO2008072723A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | ANTI-Claudin-3 MONOCLONAL ANTIBODY, AND TREATMENT AND DIAGNOSIS OF CANCER USING THE SAME |
PT2059534E (en) | 2007-02-23 | 2012-07-17 | Schering Corp | Engineered anti-il-23p19 antibodies |
JP2010518858A (en) | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | Engineered anti-IL-23P19 antibody |
AU2008260498B2 (en) | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
AU2008323701B2 (en) | 2007-11-07 | 2015-03-26 | Genentech, Inc | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
EP2594590B1 (en) | 2007-12-14 | 2014-11-12 | Bristol-Myers Squibb Company | Method of producing binding molecules for the human OX40 receptor |
JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
ATE542813T1 (en) | 2008-08-06 | 2012-02-15 | Pfizer | 6-SUBSTITUTED 2-HETEROCYCLYLAMINOPYRAZINE COMPOUNDS AS CHK-1 INHIBITORS |
JP2012501323A (en) * | 2008-08-29 | 2012-01-19 | アカデミシュ ジーケンハウス ライデン ハー.オー.デー.エン. ルムク | Delivery of a CD40 agonist to a subject's tumor draining lymph nodes |
EP2198878A1 (en) | 2008-12-18 | 2010-06-23 | University Of Miami | Polypeptide bombesin antagonists |
JO3382B1 (en) | 2008-12-23 | 2019-03-13 | Amgen Inc | Human cgrp receptor binding antibodies |
AU2016244220B2 (en) * | 2008-12-23 | 2018-05-17 | Amgen Inc. | Human CGRP receptor binding proteins |
AU2010229192A1 (en) * | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
JP5883653B2 (en) | 2009-03-10 | 2016-03-15 | ベイラー リサーチ インスティテュートBaylor Research Institute | Antigen-presenting cell targeting antiviral vaccine |
CN108373509A (en) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | The antiviral vaccine of target antigen presenting cells |
CN102448989B (en) * | 2009-03-10 | 2015-09-30 | 贝勒研究院 | Anti-CD 40 antibodies and uses thereof |
MX2011010938A (en) | 2009-04-18 | 2012-01-12 | Genentech Inc | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies. |
WO2010123012A1 (en) * | 2009-04-20 | 2010-10-28 | 協和発酵キリン株式会社 | Antibody containing igg2 having amino acid mutation introduced therein |
TW201138843A (en) | 2009-12-18 | 2011-11-16 | Colgate Palmolive Co | Biguanide preservation of precipitated calcium carbonate |
WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
ES2807217T3 (en) | 2010-03-31 | 2021-02-22 | Boehringer Ingelheim Int | Anti-CD40 antibodies |
GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
FR2959994B1 (en) | 2010-05-12 | 2012-08-24 | Lfb Biotechnologies | NOVEL 12G4 MUTUS HUMANIZED ANTIBODIES AND THEIR FRAGMENTS DIRECTED AGAINST THE HUMAN TYPE II ANTI-MULLERIAN HORMONE RECEPTOR |
EP3441404A1 (en) | 2010-09-09 | 2019-02-13 | Pfizer Inc | 4-1bb binding molecules |
AU2011310887A1 (en) * | 2010-09-29 | 2013-05-02 | Universite De Liege | Combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
JP2014500879A (en) * | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Factors and methods for treating diseases correlated with BCMA expression |
CN103347898B (en) * | 2011-01-10 | 2017-12-05 | Ct大西洋有限公司 | Including the therapeutic alliance with tumor associated antigen binding antibody |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
PT2683406T (en) | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anti-cd40 antibodies and uses thereof |
CA2830972C (en) | 2011-04-19 | 2018-11-20 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
JP6152090B2 (en) * | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | Compositions and methods for treating optic neuritis |
TWI598363B (en) | 2011-04-21 | 2017-09-11 | 必治妥美雅史谷比公司 | Antibody polypeptides that antagonize cd40 |
CN106928362B (en) | 2011-04-29 | 2021-10-26 | 埃派斯进有限公司 | anti-CD 40 antibodies and methods of use thereof |
EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
AP2014007588A0 (en) | 2011-09-22 | 2014-04-30 | Amgen Inc | CD27L antigen binding proteins |
CN104203982B (en) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | Polypeptide construct and application thereof |
WO2013091661A2 (en) * | 2011-12-23 | 2013-06-27 | Aarhus Universitet | Proteolytic resistant protein affinity tag |
RS62454B1 (en) * | 2012-01-31 | 2021-11-30 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
JP5798199B2 (en) * | 2012-03-08 | 2015-10-21 | 国立研究開発法人科学技術振興機構 | Anti-cancer agent |
AR090263A1 (en) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
RU2737765C2 (en) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Prostate-associated antigens and immunotherapeutic regimens based on vaccines |
US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
ES2873877T3 (en) | 2012-06-18 | 2021-11-04 | Ospedale San Raffaele Srl | Compositions and methods to decrease an immune response |
CN109265552A (en) * | 2012-10-30 | 2019-01-25 | 埃派斯进有限公司 | Anti-CD 40 antibodies and its application method |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
CA2899960C (en) * | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
JP2016515544A (en) | 2013-03-18 | 2016-05-30 | バイオセルオーエックス プロダクツ ビー.ブイ. | Humanized anti-CD134 (OX40) antibody and use thereof |
MX370377B (en) | 2013-04-29 | 2019-12-11 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b. |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
WO2014202552A1 (en) | 2013-06-17 | 2014-12-24 | Koninklijke Philips N.V. | Magnetic resonance imaging subject support |
GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
SI3444271T1 (en) | 2013-08-08 | 2022-03-31 | Cytune Pharma | Il-15 and il-15ralpha sushi domain based modulokines |
CA2923145A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
AR097584A1 (en) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1 |
SG10201804030WA (en) | 2013-10-25 | 2018-07-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
SG11201604594SA (en) * | 2013-12-20 | 2016-07-28 | Hoffmann La Roche | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
BR112016024546A2 (en) * | 2014-04-30 | 2018-01-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | antibody or antibody fragment, antibody or isolated antibody fragment, antibody-drug conjugate, nucleic acid molecule, host cell, and pharmaceutical composition |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
KR102443258B1 (en) | 2014-08-12 | 2022-09-14 | 엘리게이터 바이오사이언스 에이비 | Combination therapies with anti cd40 antibodies |
BR112016029334A2 (en) * | 2014-08-14 | 2018-01-09 | Hoffmann La Roche | pharmaceutical product, use of an antibody, kit, method for treating a cancer patient and methods and uses of new products |
EP3070102A1 (en) | 2015-03-18 | 2016-09-21 | F. Hoffmann-La Roche AG | Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies |
US10934362B2 (en) | 2014-09-15 | 2021-03-02 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
NZ731491A (en) | 2014-10-23 | 2021-12-24 | Kira Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
EA036498B1 (en) | 2014-10-29 | 2020-11-17 | Сиэтл Дженетикс, Инк. | Dosage and administration of non-fucosylated anti-cd40 antibodies |
MX2017005481A (en) | 2014-10-29 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd | Interferon a2b variants. |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
PT3283527T (en) | 2015-04-13 | 2021-03-03 | Five Prime Therapeutics Inc | Combination therapy for cancer |
JOP20200116A1 (en) | 2015-04-24 | 2017-06-16 | Amgen Inc | Methods for treating or preventing migraine headache |
BR122018004815A2 (en) | 2015-04-30 | 2019-09-10 | Psioxus Therapeutics Ltd | oncolytic adenovirus encoding protein b7 |
CA2985718A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
CN107771184B (en) * | 2015-06-29 | 2022-11-01 | 百时美施贵宝公司 | Antibodies against CD40 |
KR20180021833A (en) * | 2015-06-29 | 2018-03-05 | 더 락커펠러 유니버시티 | Antibodies to CD40 with enhanced agonist activity |
CN111375066B (en) | 2015-07-16 | 2023-04-25 | 百欧肯治疗有限公司 | Compositions and methods for treating cancer |
EP3307322B1 (en) | 2015-09-04 | 2021-02-17 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
ES2906823T3 (en) | 2015-09-30 | 2022-04-20 | Janssen Biotech Inc | Agonist antibodies that specifically bind to human CD40 and methods of use |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
MA43023A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | HUMAN TRANSFERRIN / ANTI-HUMAN BISPECIFIC CD20 / ANTI-HUMAN RECEPTOR ANTIBODIES AND METHODS FOR USE THEREOF |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
KR20180072821A (en) | 2015-11-03 | 2018-06-29 | 얀센 바이오테크 인코포레이티드 | Antibodies that specifically bind to PD-1 and uses thereof |
EP3757119A1 (en) * | 2015-11-16 | 2020-12-30 | Ubiprotein, Corp. | A method for extending half-life of a protein |
EP3386536A4 (en) * | 2015-12-07 | 2019-07-31 | Opi Vi- IP Holdco LLC | Composition of antibody construct-agonist conjugates and methods of use thereof |
JP7064437B2 (en) | 2015-12-17 | 2022-05-10 | サイオクサス セラピューティクス リミテッド | Group B adenovirus encoding an anti-TCR complex antibody or fragment |
MX2018010672A (en) | 2016-03-04 | 2019-05-27 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity. |
WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
CN109069638B (en) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | Trispecific inhibitors for cancer therapy |
MA43835A (en) | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINAL PRODUCTS AND THEIR INTERMEDIARIES |
US20170342169A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins |
IL263223B2 (en) | 2016-05-27 | 2023-03-01 | Abbvie Biotherapeutics Inc | Anti-cd40 antibodies and their uses |
CA3026880A1 (en) | 2016-06-08 | 2017-12-14 | Paul Foster | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
EP3470424A4 (en) | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | Sequence of antibody heavy chain constant region for enhancing agonist antibody activity |
BR112018076260A2 (en) | 2016-06-20 | 2019-03-26 | Kymab Limited | antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin |
BR112019000512A2 (en) | 2016-07-14 | 2019-04-24 | Genmab A/S | antibody, nucleic acid, expression vector, host cell, composition, methods of treating a disease, to produce a bispecific antibody and to detect if cross-linking between cd40 and cd137 expressing cells occurs in a sample, use of a multispecific antibody and kit |
JP7241677B2 (en) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Anti-CD47 combination therapy |
CN109843916B (en) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | Fc-engineered anti-TNFR superfamily member antibodies with enhanced agonistic activity and methods of use thereof |
CA3033661A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
US11905331B2 (en) | 2016-11-11 | 2024-02-20 | Kumho Ht, Inc. | Antibody binding specifically to CD40 and use thereof |
KR20190095941A (en) | 2016-12-19 | 2019-08-16 | 그렌마크 파머수티칼스 에스. 아. | New TNFR Agonists and Their Uses |
CN110072553B (en) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | Treatment of tumors with anti-CSF-1R antibodies in combination with anti-PD-L1 antibodies after failure of anti-PD-L1/PD 1 treatment |
US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
CA3049842A1 (en) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Construct-peptide compositions and methods of use thereof |
KR20190115057A (en) | 2017-02-10 | 2019-10-10 | 젠맵 비. 브이 | Polypeptide Variants and Uses thereof |
CA3056011A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
JP2020512312A (en) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | Process for the preparation of glucuronide drug-linker and its intermediates |
CA3055433A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
EP3604384B1 (en) | 2017-03-30 | 2021-09-08 | NOF Corporation | Hydrophilic polymer derivative having self-immolative acetal linker and composite using same |
EP3604385A4 (en) | 2017-03-30 | 2021-01-20 | NOF Corporation | Heterobifunctional monodispersed polyethylene glycol, and complex using same |
TWI704158B (en) * | 2017-04-04 | 2020-09-11 | 瑞士商赫孚孟拉羅股份公司 | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
CN110505883A (en) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | Proleulzin immunoconjugates used in method for treating cancer, CD40 agonist, and optionally PD-1 axis binding antagonists |
WO2018220207A1 (en) | 2017-06-01 | 2018-12-06 | Psioxus Therapeutics Limited | Oncolytic virus and method |
JP7257971B6 (en) | 2017-06-01 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Anti-CD40 Antibodies, Antigen-Binding Fragments Thereof, and Medical Uses Thereof |
TW201902462A (en) | 2017-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | Novel administration routes for immune agonists |
EP3418302A1 (en) | 2017-06-19 | 2018-12-26 | F. Hoffmann-La Roche AG | Administration routes for immune agonists |
CU20200002A7 (en) | 2017-07-14 | 2020-11-30 | Pfizer | ANTIBODIES AGAINST MADCAM |
CN111511762A (en) | 2017-08-21 | 2020-08-07 | 天演药业公司 | anti-CD137 molecules and uses thereof |
SG11202002366VA (en) | 2017-09-19 | 2020-04-29 | Mab Discovery Gmbh | Agonistic cd40 antibodies |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
EP3708589A4 (en) | 2017-11-08 | 2021-08-11 | Kyowa Kirin Co., Ltd. | BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM |
CN111788227A (en) | 2017-12-27 | 2020-10-16 | 百时美施贵宝公司 | anti-CD 40 antibodies and uses thereof |
CN109971723B (en) * | 2017-12-28 | 2023-07-07 | 上海细胞治疗研究院 | T cells comprising CD40 antibody and muc1 specific chimeric antigen receptor gene and uses thereof |
CN109971717B (en) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
JP7204078B2 (en) | 2018-03-13 | 2023-01-16 | 日油株式会社 | Heterobifunctional compounds with monodispersed polyethylene glycols in main and side chains |
CN111954719A (en) | 2018-03-26 | 2020-11-17 | 美国安进公司 | Total defucosylated glycoforms of antibodies produced in cell culture |
SG11202009629YA (en) | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
JP2021521804A (en) * | 2018-04-20 | 2021-08-30 | リビジェン バイオファーマ カンパニー リミテッド | Anti-CD40 antibody and its use |
US20200017596A1 (en) * | 2018-05-10 | 2020-01-16 | Abvision, Inc. | Monoclonal antibodies activating cd40 and uses thereof |
US20190365719A1 (en) * | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof |
WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
US10597453B2 (en) | 2018-06-29 | 2020-03-24 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
TWI803682B (en) | 2018-08-20 | 2023-06-01 | 美商輝瑞股份有限公司 | Anti-gdf15 antibodies, compositions and methods of use |
US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
KR20210097750A (en) | 2018-11-30 | 2021-08-09 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | CD40 antibody pharmaceutical compositions and uses thereof |
US20220025060A1 (en) | 2018-11-30 | 2022-01-27 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof |
US20220089758A1 (en) * | 2019-01-22 | 2022-03-24 | Revmab Biosciences Usa, Inc. | Novel anti-cd40 antibodies |
US10570210B1 (en) | 2019-03-04 | 2020-02-25 | Beijing Mabworks Biotech Co.Ltd | Antibodies binding CD40 and uses thereof |
KR20220004985A (en) | 2019-03-27 | 2022-01-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Recombinant protein with CD40 activation properties |
AU2020256828A1 (en) | 2019-04-10 | 2021-11-18 | Nankai University | Anti-CD40 antibody and use thereof |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
AU2020276931A1 (en) | 2019-05-15 | 2021-12-16 | Kyowa Kirin Co., Ltd. | Bispecific antibody binding to CD40 and FAP |
EP3971293A4 (en) | 2019-05-15 | 2023-02-08 | Kyowa Kirin Co., Ltd. | Bispecific antibody capable of binding to cd40 and gpc3 |
EP3990116A1 (en) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
WO2021062372A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
CA3156027A1 (en) | 2019-09-26 | 2021-04-01 | Nof Corporation | Heterobifunctional monodispersed polyethylene glycol having peptide linker |
CA3163358A1 (en) * | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
AR120832A1 (en) | 2019-12-20 | 2022-03-23 | Amgen Inc | MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS |
US20210214454A1 (en) * | 2020-01-10 | 2021-07-15 | Symphogen A/S | Anti-cd40 antibodies and compositions |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
CN115702002A (en) | 2020-04-23 | 2023-02-14 | 朝途生物疗法株式会社 | Improved peptide vaccines |
CA3178478A1 (en) | 2020-05-14 | 2021-11-18 | Valerie Perrine Calabro | Recombinant cd40 binding proteins and their use |
IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
BR112022024063A2 (en) | 2020-05-26 | 2023-01-31 | Inst Nat Sante Rech Med | CORONAVIRUS 2 POLYPEPTIDES OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS-COV-2) AND USES THEREOF FOR VACCINE PURPOSES |
GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
MX2023004364A (en) | 2020-10-15 | 2023-05-03 | Amgen Inc | Relative unpaired glycans in antibody production methods. |
WO2022101302A1 (en) | 2020-11-12 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
KR20230124672A (en) | 2020-12-23 | 2023-08-25 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Chlamydia vaccine based on targeting of MOMP VS4 antigen to antigen presenting cells |
TW202241479A (en) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
CA3204291A1 (en) | 2021-01-13 | 2022-07-21 | F. Hoffmann-La Roche Ag | Combination therapy |
CA3209251A1 (en) | 2021-01-29 | 2022-08-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes |
EP4284919A1 (en) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
EP4305066A1 (en) | 2021-03-09 | 2024-01-17 | Genmab A/S | Multispecific binding agents against cd40 and cd137 in therapy |
JP2024512669A (en) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Tanotransmission polypeptides and their use in the treatment of cancer |
WO2022261021A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
KR20240026185A (en) * | 2021-06-28 | 2024-02-27 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Anti-CD40 antibodies, antigen-binding fragments and medical uses thereof |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
US20230203176A1 (en) * | 2021-09-17 | 2023-06-29 | Novartis Ag | Methods For Prevention Of Graft Rejection In Xenotransplantation |
AU2022358474A1 (en) * | 2021-10-01 | 2024-03-28 | Mab Discovery Gmbh | Agonistic cd40 antibodies as immune stimulatory agents |
CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amagen, Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023088968A1 (en) | 2021-11-17 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Universal sarbecovirus vaccines |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023172890A2 (en) * | 2022-03-07 | 2023-09-14 | Agenus Inc. | Anti-ilt2 antibodies and uses thereof |
WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
CN115969997B (en) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | Antibody drug conjugate targeting CLDN18.2 and application thereof |
CN116375870B (en) * | 2022-12-30 | 2023-09-15 | 优睿赛思(武汉)生物科技有限公司 | Humanized antibody of anti-human CD40 protein, preparation method and application thereof |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US59427A (en) * | 1866-11-06 | Improvement in fences | ||
US142358A (en) * | 1873-09-02 | Improvement in the purification of illuminating-gas | ||
US439216A (en) * | 1890-10-28 | Maker | ||
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (en) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | Transformed myeloma cell line |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (en) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BONDING PAIRS |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
US5416367A (en) * | 1991-03-06 | 1995-05-16 | Quicklogic Corporation | Programmable application specific integrated circuit and logic cell therefor |
IE921169A1 (en) | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
ATE181571T1 (en) | 1991-09-23 | 1999-07-15 | Medical Res Council | METHODS FOR PRODUCING HUMANIZED ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
JPH05242071A (en) * | 1991-11-20 | 1993-09-21 | Mitsubishi Electric Corp | Control or decision/estimation of object system and its device |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
PT804070E (en) | 1993-03-09 | 2000-11-30 | Genzyme Corp | ISOLATION OF COMPONENTS OF INTEREST FROM MILK. |
CA2172376C (en) | 1993-10-01 | 2008-11-18 | William C. Fanslow, Iii | Antibodies to cd40 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
NZ278740A (en) * | 1993-12-23 | 1998-05-27 | Immunex Corp | Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein |
US5612126A (en) * | 1994-01-19 | 1997-03-18 | Burlington Industries, Inc. | Stiff fabric and method of forming the stiff fabric |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
JPH0812700A (en) | 1994-07-01 | 1996-01-16 | Sumitomo Electric Ind Ltd | Monoclonal antibody against mouse cd40 |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
GB9425060D0 (en) * | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
WO1996032181A1 (en) * | 1995-04-11 | 1996-10-17 | Robert Bosch Gmbh | Process and device for reducing pollutants, especially nitrogen oxides in combustion exhaust gases |
MX9708026A (en) | 1995-04-20 | 1997-11-29 | Pfizer | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors. |
CA2218489A1 (en) | 1995-04-21 | 1996-10-24 | Aya Jakobovits | Generation of large genomic dna deletions |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5780215A (en) * | 1995-07-26 | 1998-07-14 | Konica Corporation | Silver halide color photographic light-sensitive material |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (en) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | MATRIX METALLOPROTEASE INHIBITORS |
KR100489174B1 (en) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-anilinoquinazoline derivatives |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
ID19609A (en) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | HETEROSICLIC COMPOUNDS |
BR9710362A (en) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
CN1228083A (en) | 1996-08-23 | 1999-09-08 | 美国辉瑞有限公司 | Arylsulfonylamino hydroxamic acid derivatives |
US5817690A (en) * | 1996-08-27 | 1998-10-06 | American Home Products Corporation | 4-aminoethoxy indolone derivatives |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK1500329T3 (en) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
DK0950059T3 (en) | 1997-01-06 | 2004-11-01 | Pfizer | Cyclic sulfone derivatives |
CA2279276C (en) | 1997-02-03 | 2005-09-13 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
BR9807824A (en) | 1997-02-07 | 2000-03-08 | Pfizer | Derivatives of n-hydroxy-beta-sulfonyl-propionamide and its use as matrix metalloproteinase inhibitors |
CA2280151C (en) | 1997-02-11 | 2005-12-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2289102A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
JP2002512624A (en) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | Method for producing non-immunogenic protein |
EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
DE69838172T2 (en) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER |
AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
CN1280580A (en) | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
JP4462654B2 (en) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | Video material selection device and video material selection method |
PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
AU4009899A (en) * | 1998-05-23 | 1999-12-13 | Tanox, Inc. | Molecules targeting cd40 and tumor cells |
SK287132B6 (en) | 1998-05-29 | 2009-12-07 | Sugen, Inc. | Pharmaceutical composition containing pyrrole substituted 2-indolinone, kit containing mentioned composition and use pyrrole substituted 2-indolinone |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6114361A (en) | 1998-11-05 | 2000-09-05 | Pfizer Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
PT2112166T (en) | 1998-12-23 | 2019-01-30 | Pfizer | Human monoclonal antibodies to ctla-4 |
WO2000066155A1 (en) * | 1999-04-30 | 2000-11-09 | La Jolla Institute For Allergy And Immunology | Methods for preventing reactivation of latent virus and controlling virus replication |
US20030118588A1 (en) * | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US6482411B1 (en) * | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
GB9927757D0 (en) * | 1999-11-25 | 2000-01-26 | Kennedy Rheumatology Inst | Treatment of autoimmune diseases |
AU3662101A (en) * | 2000-02-01 | 2001-08-14 | Tanox Inc | Cd40-binding apc-activating molecules |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
MY143465A (en) | 2001-01-05 | 2011-05-13 | Pfizer | Antibodies to insulin-like growth factor i receptor |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
KR20120048644A (en) | 2004-01-09 | 2012-05-15 | 암젠 프레몬트 인코포레이티드 | Antibodies to madcam |
US10181126B2 (en) | 2012-03-13 | 2019-01-15 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2002
- 2002-11-05 AR ARP020104222A patent/AR039067A1/en active IP Right Grant
- 2002-11-06 HN HN2002000318A patent/HN2002000318A/en unknown
- 2002-11-08 EP EP10011765A patent/EP2343086A3/en not_active Withdrawn
- 2002-11-08 JP JP2003542215A patent/JP4616555B2/en not_active Expired - Fee Related
- 2002-11-08 SI SI200231036T patent/SI1476185T1/en unknown
- 2002-11-08 EP EP02802898.3A patent/EP1476185B1/en not_active Expired - Lifetime
- 2002-11-08 MX MXPA04004467A patent/MXPA04004467A/en active IP Right Grant
- 2002-11-08 US US10/292,088 patent/US7288251B2/en active Active
- 2002-11-08 EA EA200400654A patent/EA011449B1/en unknown
- 2002-11-08 ES ES02802898T patent/ES2432968T3/en not_active Expired - Lifetime
- 2002-11-08 NZ NZ533180A patent/NZ533180A/en not_active IP Right Cessation
- 2002-11-08 RS YU39204A patent/RS52484B/en unknown
- 2002-11-08 PL PL392809A patent/PL214634B1/en unknown
- 2002-11-08 CN CN201310141396.7A patent/CN103450360B/en not_active Expired - Lifetime
- 2002-11-08 WO PCT/US2002/036107 patent/WO2003040170A2/en active Application Filing
- 2002-11-08 ME MEP-2008-814A patent/ME00503B/en unknown
- 2002-11-08 AP APAP/P/2004/003034A patent/AP1918A/en active
- 2002-11-08 HU HU0402247A patent/HU229829B1/en unknown
- 2002-11-08 GT GT200200228A patent/GT200200228A/en unknown
- 2002-11-08 KR KR1020047006992A patent/KR100830086B1/en active IP Right Grant
- 2002-11-08 MY MYPI20024189A patent/MY137641A/en unknown
- 2002-11-08 CN CN028245709A patent/CN1582165B/en not_active Expired - Lifetime
- 2002-11-08 GE GE5640A patent/GEP20074222B/en unknown
- 2002-11-08 DK DK02802898.3T patent/DK1476185T3/en active
- 2002-11-08 PL PL370514A patent/PL214289B1/en unknown
- 2002-11-08 BR BRPI0214137A patent/BRPI0214137B8/en not_active IP Right Cessation
- 2002-11-08 PT PT28028983T patent/PT1476185E/en unknown
- 2002-11-08 AU AU2002356926A patent/AU2002356926B2/en not_active Expired
- 2002-11-08 OA OA1200400136A patent/OA12725A/en unknown
- 2002-11-08 IL IL16182302A patent/IL161823A0/en unknown
- 2002-11-08 CA CA2466128A patent/CA2466128C/en not_active Expired - Lifetime
- 2002-11-09 EG EG2002111224A patent/EG25801A/en active
- 2002-11-11 TW TW091133017A patent/TWI331040B/en not_active IP Right Cessation
- 2002-11-11 UY UY27537A patent/UY27537A1/en not_active Application Discontinuation
- 2002-11-11 PE PE2002001093A patent/PE20030846A1/en active IP Right Grant
- 2002-11-11 TW TW099114882A patent/TWI338579B/en not_active IP Right Cessation
- 2002-11-11 NI NI200200128A patent/NI200200128A/en unknown
- 2002-11-11 DO DO2002000507A patent/DOP2002000507A/en unknown
- 2002-11-12 PA PA20028557701A patent/PA8557701A1/en unknown
-
2004
- 2004-04-05 MA MA27607A patent/MA27139A1/en unknown
- 2004-05-04 EC EC2004005093A patent/ECSP045093A/en unknown
- 2004-05-05 TN TNP2004000078A patent/TNSN04078A1/en unknown
- 2004-05-06 IL IL161823A patent/IL161823A/en active IP Right Grant
- 2004-05-06 IS IS7253A patent/IS2940B/en unknown
- 2004-05-10 CU CU20040097A patent/CU23745A3/en active IP Right Grant
- 2004-05-13 CR CR7343A patent/CR7343A/en unknown
- 2004-05-28 ZA ZA2004/04207A patent/ZA200404207B/en unknown
- 2004-06-08 NO NO20042388A patent/NO334339B1/en not_active IP Right Cessation
- 2004-06-08 HR HRP20040525AA patent/HRP20040525B1/en not_active IP Right Cessation
-
2005
- 2005-03-22 HK HK05102440.7A patent/HK1069122A1/en not_active IP Right Cessation
- 2005-08-25 US US11/211,917 patent/US7338660B2/en not_active Expired - Lifetime
- 2005-08-26 US US11/213,575 patent/US7563442B2/en active Active
-
2007
- 2007-09-25 US US11/904,295 patent/US7618633B2/en not_active Expired - Lifetime
-
2008
- 2008-09-22 US US12/284,605 patent/US7626012B2/en not_active Expired - Lifetime
-
2009
- 2009-06-19 CR CR10878A patent/CR10878A/en unknown
- 2009-08-27 CL CL2009001779A patent/CL2009001779A1/en unknown
- 2009-10-09 US US12/576,459 patent/US20100098694A1/en not_active Abandoned
-
2010
- 2010-03-31 JP JP2010081224A patent/JP5547532B2/en not_active Expired - Fee Related
-
2012
- 2012-05-14 US US13/471,395 patent/US8388971B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/619,954 patent/US20130024956A1/en not_active Abandoned
- 2012-12-12 JP JP2012270885A patent/JP5848232B2/en not_active Expired - Lifetime
-
2013
- 2013-10-16 CY CY20131100904T patent/CY1115675T1/en unknown
-
2015
- 2015-08-06 US US14/820,040 patent/US20160152713A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE45847E1 (en) | 2004-01-09 | 2016-01-19 | Pfizer Inc. | Antibodies to MAdCAM |
US9221915B2 (en) | 2005-09-07 | 2015-12-29 | Pfizer Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7618633B2 (en) | Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses | |
AU2002356926A1 (en) | Antibodies to CD40 | |
CA2885172C (en) | Antibodies to m-csf | |
EP1660127A1 (en) | Antibodies to c-met |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-392/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 566/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2466128 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 161823 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200400414 Country of ref document: VN Ref document number: 1020047006992 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/004467 Country of ref document: MX Ref document number: 2003542215 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: AP/P/2004/003034 Country of ref document: AP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002356926 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/04207 Country of ref document: ZA Ref document number: 533180 Country of ref document: NZ Ref document number: 200404207 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2004000146 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20040525A Country of ref document: HR Ref document number: 04053734 Country of ref document: CO Ref document number: 200400654 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5640 Country of ref document: GE Ref document number: 8256 Country of ref document: GE Ref document number: 2002802898 Country of ref document: EP Ref document number: 20028245709 Country of ref document: CN |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/19-19/19, DRAWINGS, REPLACED BY CORRECT PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-500651 Country of ref document: PH |
|
WWP | Wipo information: published in national office |
Ref document number: 2002802898 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002356926 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2009-010878 Country of ref document: CR |